Intensive Care Medicine

Original article Un-edited accepted proof

Low-dose Methylprednisolone Treatment in Critically Ill Patients with Severe Community-acquired Pneumonia

G. Umberto Meduri, MD[a,b], Mei-Chiung Shih, PhD[c,d], Lisa Bridges, ACNP, BC[a,b], Thomas J. Martin, MD[e,f,g], Ali El-Solh, MD, MPH[h,i], Nitin Seam, MD[j], Anne Davis-Karim, PharmD[k], Reba Umberger, PhD, RN, CCRN-K[b], Antonio Anzueto, MD[l,m], Peruvemba Sriram, MD[n], Charlie Lan, DO[o], Marcos I. Restrepo, MD[l,m], MSc, PhD, Juan J. Guardiola, MD[p,q], Teresa Buck, MD[r], David P. Johnson, MD[r], Anthony Suffredini, MD[j], W. Andrew Bell, PharmD[s], Julia Lin, PhD[c], Lan Zhao, MS[c], Lauren Uyeda, MA[c], Lori Nielsen, BA[c], Grant D. Huang, MPH, PhD[t], for the ESCAPe Study Group*

[a]Memphis VA Medical Center
[b]University of Tennessee Health Science Center
[c]VA Cooperative Studies Program Coordinating Center, Palo Alto
[d]Department of Biomedical Data Sciences, Stanford University
[e]Salem VA Health Care System
[f]Virginia Tech Carilion School of Medicine
[g]Edward Via Virginia College of Osteopathic Medicine
[h]VA Western New York Health Care System
[i]University at Buffalo
[j]National Institutes of Health Clinical Center
[k]VA Cooperative Studies Program Pharmacy Coordinating Center
[l]South Texas Veterans Health San Antonio
[m]University of Texas Health Science Center
[n]Malcom Randall VA Medical Center
[o]Michael E Debakey VA Medical Center
[p]Robley Rex VA Medical Center
[q]University of Louisville
[r]Bay Pines VA Healthcare Center
[s]Renown Health, Reno, NV
[t]Office of Research and Development, Department of Veterans Affairs

Intensive Care Medicine

Original article Un-edited accepted proof

The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or any U.S. governmental agency.

Trial Registration: ESCAPe [Extended Steroid (in) CAP(e)] ClinicalTrials.gov, number NCT01283009

(Funded by U.S. Department of Veterans Affairs)

Corresponding Author: G. Umberto Meduri, MD, Memphis VA Medical Center - Pulmonary, Critical Care and Sleep Medicine Services. Email: Gianfranco.Meduri@va.gov and gmeduri@uthsc.edu

DOI: 10.1007/s00134-022-06684-3

Take-home message

In this double-blind, randomized, placebo-controlled clinical trial of 584 participants hospitalized with severe community-acquired pneumonia, prolonged methylprednisolone treatment did not significantly reduce 60-day all-cause mortality or improve secondary outcomes during initial hospitalization or up to one year of follow-up. The risk for complications was similar to the control group.

ABSTRACT

Purpose: Severe community-acquired pneumonia (CAP) requiring intensive care unit admission is associated with significant acute and long-term morbidity and mortality. We hypothesized that downregulation of systemic and pulmonary inflammation with prolonged low-dose methylprednisolone treatment would accelerate pneumonia resolution and improve clinical outcomes.

Methods: This double-blind, randomized, placebo-controlled clinical trial recruited adult patients within 72-96 hours of hospital presentation. Patients were randomized in 1:1 ratio; an intravenous 40 mg loading bolus was followed by 40 mg/day through day 7 and progressive tapering during the 20-day treatment course. Randomization was stratified by site and need for mechanical ventilation (MV) at the time of randomization. Outcomes included a primary endpoint of 60-day all-cause mortality and secondary endpoints of morbidity and mortality up to one year of follow-up.

Results: Between January 2012 and April 2016, 586 patients from 42 Veterans Affairs Medical Centers were randomized, short of the 1420 target sample size because of low recruitment. 584 patients were included in the analysis. There was no significant difference in 60-day mortality between the methylprednisolone and placebo arms (16% vs. 18%; adjusted odds ratio 0.90, 95% CI 0.57 to 1.40). There were no significant differences in secondary outcomes or complications.

Conclusions: In patients with severe CAP, prolonged low-dose methylprednisolone treatment did not significantly reduce 60-day mortality. Treatment was not associated with increased complications.

Keywords: Community-acquired pneumonia, Glucocorticoids, Intensive care, Methylprednisolone, Randomized clinical trial.

Word counts: 3230

Introduction

Pneumonia is the leading cause of community-acquired infection requiring intensive care unit (ICU) admission and a common precipitant of septic shock and acute respiratory distress syndrome (ARDS).[1] [Hospital mortality is higher for patients who are older, bacteremic,[2] have more comorbidities,[3] meet criteria for healthcare-associated pneumonia (HCAP), require mechanical ventilation (MV) or vasopressor support, or are transferred to the ICU from a medical ward.[4]] Most hospital deaths occur after eradication of bacteria from tracheal secretions and the bloodstream,[5, 6] implying that adequate antibiotic treatment alone may be insufficient in further improving outcomes. Importantly, patients surviving hospitalization remain at risk for long-term morbidity,[7] re-hospitalizations,[4] and increased post-discharge mortality at one year (21%-40%)[4] and up to 5 years.[8] Evidence points to the host's inability to fully down-regulate systemic inflammation and restore tissue homeostasis as the dominant pathophysiologic processes contributing to acute and chronic adverse outcomes in community-acquired pneumonia (CAP).[9, 10]

Glucocorticoids were investigated in multiple randomized trials, with a signal for benefit in patients with severe pneumonia;[11, 12] however, a large confirmatory study was lacking. The Department of Veterans Affairs (VA) Cooperative Study #574 evaluated the efficacy of prolonged methylprednisolone treatment on short- and long-term morbidity and mortality in patients admitted to the ICU with severe CAP. We hypothesized that a 20-day low-dose methylprednisolone treatment would reduce 60-day mortality and improve clinical outcomes. The rationale for a 20-day treatment was to support the resolution phase of the disease,[13] incorporate adequate glucocorticoid tapering[14] and to reduce post-hospitalization low-grade systemic inflammation.

Methods

Trial Design and Oversight

A double-blind, randomized, placebo-controlled trial was conducted at 42 VA Medical Centers from January 1, 2012 to August 31, 2016. Eligible patients were randomly assigned in a 1:1 ratio to either methylprednisolone or placebo. The trial protocol and the statistical analysis plan are provided in the Supplement Appendix.

The trial was approved by the VA Central Institutional Review Board and conducted in accordance with Good Clinical Practice Guidelines. An independent Data Monitoring Committee monitored patient safety, study conduct and data. The authors vouch for the accuracy and completeness of the data and statistical analyses and for the fidelity of the trial to the protocol.

Participants

Adult patients presenting with a clinical diagnosis of severe CAP/HCAP were enrolled within 72-96 hours (additional 24 hours in patients not yet meeting severity criteria) of hospital presentation. Inclusion criteria required the presence of one major or three minor modified American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for severe pneumonia[15] as well as admission to intensive or intermediate care. Eligibility criteria are detailed in the Trial Protocol (Supplement Appendix).

Treatment and Other Trial Procedures

Written informed consent was obtained from each participant or their legally authorized representative if they were unable to provide consent. Participants were randomly assigned in a

1:1 ratio to receive methylprednisolone or placebo using random permuted blocks of sizes 2 and 4, stratified by study site and need for MV at enrollment.

Methylprednisolone or placebo was given in a double-blind fashion. On the day of randomization (Day 0), an intravenous loading dose of 40 mg was given, followed by maintenance infusion. The full 20-day treatment course included 40 mg/day on Days 1-7, 20 mg/day on Days 8-14, 12 mg/day on Days 15-17 and 4 mg/day on Days 18-20. Study drug was given by continuous infusion during ICU stay and changed to twice per day, via intravenous or enteral administration, after ICU discharge. Participants in both groups received standardized care following consensus recommendations.[15, 16]

Participants were assessed daily up to day 8 during the initial ICU stay, at hospital discharge, and on days 28, 60, and 180. The final one-year follow-up for mortality and rehospitalizations was performed through review of records. We attempted to assess all participants regardless of treatment continuation. Monitoring for serious adverse events (SAEs) continued until the final follow-up contact. Safety monitoring and reporting procedures are detailed in the Trial Protocol.

Outcomes

The primary outcome was all-cause mortality at 60 days. Secondary outcomes included: (1) During hospitalization: post-randomization development of vasopressor-dependent shock or ARDS; number of multiple organ dysfunction syndrome (MODS)-free days to day 8; MV-free days up to days 8 and 28; duration of ICU and hospital stay; potential complications associated with methylprednisolone treatment; and hospital mortality; (2) Post discharge: cardiovascular complications within 180 days of randomization; quality of life and functional status at days 28, 60 and 180; number and causes of re-hospitalization at VA hospitals within one year; SAEs and complications; and all-cause mortality at days 180 and 365. Exploratory outcome included

duration of MV. MODS was assessed using the Sequential Organ Failure Assessment score.[17] Health-related quality of life was measured by the Veterans RAND 12 Item Health Survey. [18, 19] Functional status was measured by the Activities of Daily Living Scale and the Instrumental Activities of Daily Living Scale.[20, 21] Outcome definitions are detailed in the protocol.

Statistical Analysis

We estimated that 1406 participants randomized 1:1 to the two treatment groups would provide 85% power to detect a 7% absolute reduction in 60-day mortality (21% in the methylprednisolone group vs. 28% in the placebo group). The original plan was to randomize 1420 participants (accounting for 1% attrition in primary outcome) over 5 years (January 2012 to December 2016) and conduct two interim analyses at approximately 50% and 75% of the target number of participants to allow early discontinuation for efficacy (based on two-sided boundaries[22]) or futility (based on conditional power). Because of low recruitment, an ad hoc interim futility analysis was conducted on April 8, 2015 based on data as of February 6, 2015. At that time, 431 participants were randomized and the primary outcome was available for 372 participants. A one-sided non-binding futility boundary was calculated.[22] Conditional power was calculated for a range of differences in 60-day mortality (0%-10%) and for two different target numbers of patients with 60-day mortality (the original target 1406 and the projected sample size 800 by December 2016). Based on the information, the DMC supported continued recruitment until the end of the planned recruitment period (December 2016). Study enrollment was stopped on April 30, 2016 due to persistent low recruitment; the final number of randomizations was 586. No additional interim analysis was done. Study follow-up ended in August 2016, which allowed collection of primary outcomes for all randomized participants. We report data for 584 participants because two participants were improperly consented, and their data cannot be used for analyses.

Primary analyses were performed on the intention-to-treat sample (n= 584). Sixty-day all-cause mortality was compared by Chi-square test. The difference in percentages of 60-day mortality and the 95% confidence interval (CI) were calculated. Generalized linear mixed effect models were used to adjust for site (as a random effect) and baseline patient characteristics (as fixed effects), including MV status at randomization, age, Acute Physiology and Chronic Health Evaluation (APACHE) III score, bacteremia, use of anti-inflammatory medications and use of macrolide antibiotics at baseline. Pneumonia Severity Index[23] class and Simplified Acute Physiology Score (SAPS) III score [24] were not included in the model to reduce collinearity of the covariates. Sensitivity analyses were performed to assess robustness of results and included using the per-protocol sample and different imputation methods for 21 participants missing primary outcomes (all due to early study withdrawal). The results from imputations were similar and not shown. Kaplan-Meier estimate of survival probability at day 60 was also calculated. Pre-specified subgroup analyses included MV status at randomization, APACHE III score quartiles, and CAP versus HCAP; post hoc subgroup analyses included severity of CAP, adequacy of initial antibiotic treatment, ARDS at baseline, and time of study treatment initiation (within 48 hours vs. >48 hours of hospital presentation). Logistic regression was used to examine subgroups by treatment interactions.

Secondary outcomes were compared using Chi-square test or Fisher's exact test for categorical outcomes, two-sample t-tests or Wilcoxon rank-sum tests for continuous outcomes, and log rank tests and Kaplan-Meier curves for time to death and duration of MV up to day 28. Survival up to 180 days was compared by the restricted mean survival time (RMST). [25]

All p-values are two-sided. The p-values for secondary and exploratory outcomes were adjusted for multiplicity by the Bonferroni method, separately for in-hospital outcomes and post-discharge outcomes. The widths of the confidence intervals for the treatment differences in secondary and exploratory outcomes were not adjusted for multiplicity. SAS 9.4 (SAS Institute,

Cary, NC, USA) was used for analysis. Unless specified otherwise, results are reported as methylprednisolone vs. placebo.

Results

Patients

Of the 3936 patients who were assessed for eligibility, 584 were randomized; 70% were randomized within 48 hours of hospital presentation and 94% within 72 hours (median time to randomization, 37 hours). Two hundred and ninety-seven participants were assigned to the methylprednisolone group and 287 to the placebo group (Figure 1); 193 (33.0%) were receiving MV at the time of randomization. A total of 382 (65%) participants started study treatment within 48 hours of hospital presentation and 513 (88%) within 72 hours (median time from hospital presentation to study treatment initiation, 40 hours). The study flow diagram is shown in Figure 1, which also provides information on study drug withdrawal and reasons.

The two treatment groups were balanced in demographics and baseline patient characteristics (Table 1). The mean age was 68.8 years, 96% were male, 83% were White. Patients had an average of four major comorbidities (Table S1). Thirty-four percent of participants met HCAP criteria, 69% had multi-lobar involvement on chest radiograph, 15% had bacteremia, 11% had ARDS at enrollment, and 13% had vasopressor-dependent shock at enrollment. Pathogens potentially responsible for the pneumonia were identified in 250 (43%) of the 577 participants with specimens from the respiratory tract, pleural fluid, blood or urine. The most common pathogens isolated were *Staphylococcus aureus* (10%), *Streptococcus pneumoniae* (9%), *Pseudomonas aeruginosa* (3%), *Escherichia coli* (3%). Initial antibiotic treatment was deemed adequate in 96% of the participants based on ATS/IDSA guideline recommendations.

Primary Outcome

There was no significant difference in 60-day all-cause mortality (16% vs. 18%; unadjusted absolute risk difference -2%, 95%CI, -8% to 5%; unadjusted odds ratio (OR) 0.89, 95%CI, 0.58 to 1.38; p=0.61) (Table 2). The result was similar when adjusted for site and MV status at randomization (adjusted OR 0.90; 95%CI, 0.57 to 1.40; p=0.63) and when also adjusted for baseline patient characteristics (adjusted OR, 0.87; 95%CI, 0.53 to 1.42; p=0.58). Kaplan-Meier estimate of 60-day mortality was 16% (95%CI, 12% to 21%) in the methylprednisolone group and 18% (95%CI, 14% to 23%) in the placebo group. No significant variation was found in the treatment effect across study sites. Results were similar in the per-protocol sample (Table S2 and Table S3). There was no significant between-group difference in the subgroup analyses (Table S4 and Figure 3).

Secondary Outcomes

In-Hospital Morbidity and Mortality

There were no significant differences between the treatment groups in development of vasopressor-dependent shock, development of ARDS, MV-free days up to days 8 or 28, duration of ICU stay (median 3 vs. 4 days; p=1.00), duration of hospital stay (median 7 vs. 8 days; p=1.00), or hospital mortality (12% vs. 10%; p=1.00) (Table 2). Among the 25 (12 vs. 13) participants who developed new shock or ARDS, 5 (1 vs. 4) stopped study medication to receive open label glucocorticoid treatment. Among participants who required MV at randomization, there was a 3-day reduction in median duration of MV (median 4 vs. 7 days; hazard ratio (HR) 1.44; 95%CI, 1.04 to 1.99; p=0.21 after Bonferroni correction).

Post-Discharge Morbidity and Mortality

There were no significant between-group differences in cardiovascular complications, quality of life, functional status, or re-hospitalizations (Table 2). The most common reasons for re-

hospitalization were pneumonia (20%), congestive heart failure (18%), and chronic obstructive pulmonary disease (COPD) (17%).

The two treatment groups had similar 180-day mortality (21% vs. 24%; OR 0.86; 95%CI, 0.58 to 1.29; p=1.00) and RMST up to day 180 (151 days vs. 149 days; difference 2.5 days; 95%CI, -7.7 to 12.6 days; p=1.00) (Table 2). Kaplan-Meier estimate of mortality by 180 days was 20% (95%CI, 16% to 26%) in the methylprednisolone group and 23% (95%CI, 19% to 29%) in the placebo group. The two groups also had similar one-year mortality (30% vs. 33%; OR 0.88; 95%CI, 0.61 to 1.27; p=1.00) and time to death (HR 0.90; 95%CI, 0.66 to 1.22; p=1.00) (Table 2 and Figure 2A). Results of secondary outcomes were similar in the per-protocol sample (Table S2) and within the MV (Table S5 and Figure 2B) and non-MV strata (Table S6 and Figure 2C). Within each stratum, the two treatment groups had similar baseline characteristics (Table S7 and Table S8).

Cause of Death

No apparent between-group differences in immediate or underlying cause of death were observed for all deaths, deaths up to day 60, deaths during initial hospitalization, or deaths after discharge from initial hospitalization (Tables S9 and S10).

Adverse Events

During the 180 days after randomization, 365 SAEs occurred in 167 (56.2%) participants in the methylprednisolone group, and 342 SAEs occurred in 162 (56.4%) participants in the placebo group (Table S11). There were no significant differences between treatment arms in SAEs (Table S11) or complications (Table S12) during 180 days after randomization or in in-hospital or post-discharge complications (data not shown).

Discussion

The ESCAPe trial showed that, in participants admitted to the ICU with severe CAP or HCAP, a 20-day treatment with low-dose methylprednisolone did not significantly reduce all-cause 60-day mortality, the primary outcome. We observed a 3-day reduction in median duration of MV in participants who required MV at randomization, although the certainty of this finding may be low given the small sample size in this subgroup, the imprecision of the estimated difference and lack of multiplicity correction. No other significant differences were found in morbidity or mortality outcomes or complications during one year of follow-up.

To our knowledge, this is the largest trial investigating the efficacy of adjunct glucocorticoids on patients with severe pneumonia requiring ICU admission and the first randomized controlled trial (RCT) designed to evaluate both short- and long-term outcomes. We review our findings in the context of recent literature. In the last fifteen years, eleven published RCTs investigated prolonged glucocorticoid treatment in patients hospitalized with bacterial CAP (n=1808);[11, 26] six of the largest RCTs (n=1506) were part of an individual patient data meta-analysis.[27]

We did not find a significant reduction in 60-day mortality or mortality up to one year, which is contrary to the observed reduction in 30-day mortality in severe CAP meta-analyses.[11, 26] The timing for glucocorticoid administration in this study may have missed the optimal window for intervention. Our study allowed for randomization up to 72-96 hours after hospital admission. While 65% of study participants initiated study treatment within 48 hours of hospital presentation and 88% within 72 hours, the inherent delay in the initiation of anti-inflammatory therapy occurred during the initial peaks of inflammatory mediators in response to invasive microbial pathogens[28] and may have attenuated potential benefits.[29] Secondly, the methylprednisolone dose of 40 mg/day may be inadequate to achieve the level of glucocorticoid receptor saturation necessary

for optimal anti-inflammatory response; a higher dose was found effective in ARDS (most attributed to pneumonia).[30] Thirdly, compared to the prior largest RCT on severe CAP,[31] our patient population was sicker, as evidenced by oxygenation indices, need for MV, and a greater burden of comorbidities associated with glucocorticoid resistance such as chronic pulmonary and cardiovascular diseases.[32] Fourth, the observed mortality in the control group was substantially lower than what was used for the power calculation. Fifth, the broad range of severity across our study cohort likely represented different pathophysiologic processes of which corticosteroids possibly have a heterogeneous effect.

For secondary and exploratory outcomes, the one-day reduction in median hospitalization duration (95%CI, -2.3 to 0.3 days) was similar to that reported in meta-analysis[27] and mainly driven by a 2.6-day reduction in the MV stratum (95%CI, -6.2 to 1.1 days). Contrary to prior investigations, we did not observe significant reduction in progression to shock or ARDS[26], increased risk for re-hospitalization,[27] or lower myocardial infarction incidence.[33]

The longer duration of methylprednisolone treatment in our trial was not associated with an increased risk of SAEs or complications within 180 days after randomization. These findings are consistent with those of updated meta-analyses of ICU patients with pneumonia,[26] septic shock,[34] and ARDS,[30] underscoring the safety of prolonged glucocorticoid treatment in this population.

Response to glucocorticoid treatment may be affected by the severity of dysregulated systemic inflammation.[31, 35, 36] In a RCT in patients with severe CAP and C-reactive protein (CRP) levels >150 mg/L, methylprednisolone was found to reduce treatment failure.[31] In a retrospective cohort study in patients with severe CAP admitted to ICU and receiving glucocorticoid treatment, the subgroup with CRP levels > 150 mg/L had faster recovery of hypoxemia and increased ICU- and hospital-free days.[35] These findings suggest that biologic markers may help identify patients most likely to benefit from glucocorticoid treatment. The blood

samples collected in ESCAPe will allow examination of the relationship between clinical outcomes and markers of systemic inflammation over time, which may provide the groundwork for development of personalized glucocorticoid treatment strategies.[30]

Evidence of glucocorticoid benefits in severe COVID-19 pneumonia[37, 38] and ARDS[39] has generated greater interest in this field of research. The safety of prolonged methylprednisolone treatment has been confirmed.[11, 26, 27] However, notable treatment heterogeneity in published protocols,[30] such as the specific glucocorticoid, timing of initiation, dosage, duration, mode of administration, and tapering strategy, underscore the need for a more uniform approach. Further studies are required to clarify how these treatment components impact clinical outcomes and host responses. During the pandemic, variability in response to glucocorticoid treatment was observed, leading clinicians to adjust dosage and duration based on markers of inflammation and oxygenation. This has called attention to an underappreciated aspect of glucocorticoid treatment, the great interindividual variability in (i) achieved blood drug levels[40] and (ii) intracellular glucocorticoids receptor sensitivity,[41] areas in need of research.[30]

This trial has several limitations. First, enrollment was stopped before reaching the target sample size 1420 because of low recruitment. The main contributing factor to low recruitment was that the proportion of the patient population meeting study eligibility criteria was lower than anticipated (26% versus anticipated 70%), even though the consent rate for eligible patients was higher than anticipated (57% versus anticipated 30%). Another contributing factor was two years of relatively low influenza activity during the recruitment period. Second, the certainty of our overall study findings may be limited given that the sample size was lower than target and the analyses may be underpowered. Third, delayed initiation of anti-inflammatory therapy may have attenuated the differences between the treatment groups.[29] Fourth, the VA population is predominantly older, male, and with multiple comorbidities compared to the general

population;[27] therefore the trial's results may not be generalizable to non-Veterans. Fifth, the high proportion of patients excluded due to physician opinion of not being a viable candidate might indicate a potential risk of selection bias. Sixth, this study excluded patients with recent or concurrent use of glucocorticoids; thus, it cannot determine if patients with severe CAP who require a short course of glucocorticoids for co-morbid diseases (such as COPD) would benefit from prolonged glucocorticoid treatment.

Conclusion

In patients with severe CAP, prolonged low-dose methylprednisolone treatment did not significantly reduce 60-day mortality. The risk for complications was similar to the control group.

ARTICLE INFORMATION

Author Affiliations:

Meduri, Bridges: Memphis VA Medical Center

Meduri, Bridges, Umberger: University of Tennessee Health Science Center

Shih, Zhao, Uyeda, Nielsen: VA Cooperative Studies Program Coordinating Center, Palo Alto

Shih: Department of Biomedical Data Sciences, Stanford University

Martin: Salem VA Health Care System; Virginia Tech Carilion School of Medicine; Edward Via Virginia College of Osteopathic Medicine

El-Solh: VA Western New York Health Care System; University at Buffalo

Seam, Suffredini: National Institutes of Health Clinical Center

Davis-Karim: VA Cooperative Studies Program Pharmacy Coordinating Center

Anzueto, Restrepo: South Texas Veterans Health Care System; University of Texas Health Science Center

Sriram: Malcom Randall VA Medical Center

Lan: Michael E Debakey VA Medical Center

Guardiola: Robley Rex VA Medical Center; University of Louisville

Buck, Johnson: Bay Pines VA Healthcare Center

Bell: Renown Health, Reno, NV

Huang: Office of Research and Development, Department of Veterans Affairs

Author Contributions:

Drs. Meduri and Shih had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the analyses.

Study concept and design: Meduri, Shih, Bridges, Seam, Davis-Karim, Restrepo, Suffredini, Bell, Lin, Huang

Acquisition of the data: Martin, El-Solh, Anzueto, Sriram, Lan, Restrepo, Guardiola, Buck, Johnson

Analysis and interpretation of data: Meduri, Shih.

Drafting of the manuscript: Meduri, Shih.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Shih, Zhao, Uyeda.

Obtaining funding: Meduri, Shih.

Administrative, technical, or material support: Meduri, Shih, Bridges, Lin, Nielsen.

Conflict of Interest Disclosures:

Drs. Shih, Huang, and all unlisted members of the ESCAPe LSI Author Group have no funding or other conflicts to report.

Funding/Support:

This study was conducted with support from the VA Cooperative Studies Program. However, the views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or any US governmental agency.

Role of the Sponsor:

The VA Cooperative Studies program was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation of the manuscript. The data from the 42 sites were maintained by the VA Cooperative Studies Program Coordinating Center in Palo Alto, CA, where Mei-Chiung Shih, PhD, performed all statistical analyses with assistance from Lan Zhao, MS, and Lauren Uyeda, MA.

Data Sharing Statement: See Supplement Appendix.

Acknowledgements: We dedicate this work to the memory of Dr. Timothy D. Bigby, Principal Investigator at the San Diego VA; his warmth, kindness and professional commitment is missed by all those that had the privilege of working with him. Additional recognition goes to Kelvin K.

Lee, PhD, Valerie McGuire, PhD, and Colleen Fitzsimmons (VA Palo Alto Cooperative Studies Program Coordinating Center), Stuart Warren, David Pittman and Jolene Day (VA Albuquerque Cooperative Studies Program Pharmacy Coordinating Center), Jennifer Ransom, MPH, CCRP (Memphis VA Medical Center Chair's Office). We also wish to the thank the Veterans whose participation made the study possible.

ESCAPe Study Group Members

1. (VA Asheville Health Care System): Khalid Bashir
2. (Atlanta VA Medical Center) Octavian Ioachimescu
3. (Bay Pines VA Health Care System) Theresa Buck, David Johnson
4. (Buffalo VA Medical Center) Ali El Solh
5. (VA Charleston Health Care System) Michael Frye
6. (VA Cincinnati Health Care System) Ralph Panos
7. (Louis Stokes Cleveland VA Medical Center) Mohammad Shatat,
8. (VA Columbia South Carolina Health Care System) Enoch Gray, Brian Smith, Myron Kung
9. (VA North Texas Health Care System) James Cutrell, Roger Bedimo
10. (Malcom Randall VA Medical Center, Gainesville) Peruvemba Sriram
11. (Michael E. DeBakey VA Medical Center, Houston) Charlie Lan, Padmashi Rastogi
12. (Richard L. Roudebush VA Medical Center, Indianapolis) John Callaghan, Chadi Hage, MD
13. (Kansas City VA Medical Center) Mark Plautz
14. (VA Lexington Health Care System) Takako Schaninger, Richard Greenberg
15. (VA Loma Linda Health Care System) Lennard Specht
16. (VA Long Beach Health Care System) Catherine Sassoon
17. (Louisville VA Medical Center) Juan Guardiola, Julio Ramirez
18. (VA Memphis Health Care System) Muthiah P. Muthiah
19. (VA Miami Health Care System) Roland Schein
20. (VA Milwaukee Health Care System) Andreea Antonesu-Turcu
21. (VA Minneapolis Health Care System) Kathryn Rice
22. (VA Oklahoma City Health Care System) Houssein Youness
23. (Omaha VA Medical Center) Lee Morrow
24. (VA Palo Alto Health Care System) Ware Kuschner
25. (Phoenix VA Health Care System) Lilibeth Pineda, Richard Allen Robbins
26. (VA Pittsburgh Health Care System) Sharon Camhi
27. (VA Providence Health Care System) Matthew Jankowich
28. (VA Sierra Nevada Health Care System, Reno) Waseem Ahmed

29. (VA Salem Health Care System) Thomas Martin, Mitchell Horowitz
30. (VA Salt Lake City Health Care System) John Nord, Mark Elstad
31. (VA South Texas Health Care System, San Antonio) Marcos I. Restrepo, Antonio Anzueto
32. (VA San Diego Health Care System) Timothy Bigby*
33. (VA Carribbean Health Care System, San Juan) William Rodriguez-Cintron
34. (VA Puget Sound Health Care System, Seattle) Vincent Fan
35. (VA Syracuse Health Care System) Pratibha Kaul
36. (Tucson VA Medical Center) Michael Habib
37. (Washington DC VA Medical Center) Nitin Seam
38. (Greater Los Angeles Health Care System) Guy Soo Hoo

Acknowledgements: We dedicate this work to the memory of Dr. Timothy D. Bigby, Principal Investigator at the San Diego VA; his warmth, kindness and professional commitment is missed by all those that had the privilege of working with him. Additional recognition goes to Kelvin K. Lee, PhD, Valerie McGuire, PhD, and Colleen Fitzsimmons (VA Palo Alto Cooperative Studies Program Coordinating Center), Stuart Warren, David Pittman and Jolene Day (VA Albuquerque Cooperative Studies Program Pharmacy Coordinating Center), Jennifer Ransom, MPH, CCRP (Memphis VA Hospital Chair's Office).

Veterans Affairs Medical Centers participating in the ESCAPe trial.

Participating VAMCs in alphabetical order (ESCAPe site personnel in parenthesis): Asheville, (Khalid Bashir, Whitney Sprinkle, Webster Bazemore, Sujatha Goli, John Lucke, Valerie Allen); Atlanta, (Octavian Ioachimescu, Tiffany Elliott, Amy Anderson, Joanne Allam, Ashish Mehta, Patricia Noren, Vidisha Tanukonda); Bay Pines, (Theresa Buck, David Johnson, Caitlin Butler, James Blankenship, Patricia Ellis, Minhaj Siddiqui, Lynn Anderson); Buffalo, (Ali El-Solh, Lynne Frydrych, Karin Provost, Rachel LaPorta, Philippe Jaoude, Leah Vermont); Charleston, (Michael Frye, Leslie Harrell); Cincinnati, (Ralph Panos, Laura Lach, Dennis McGraw, Nishant Gupta, William Eschenbacher); Cleveland, (Mohammad Shatat, Kimberley Byrne, Frank Jacono, Puja Van Epps); Columbia, (Enoch Gray, Brian Smith, Myron Kung, Joanna Snead, Justin Reynolds, Mohammed Wallam, Shilpa Patel, Stuart Smith, Kathryn Mason, Heather Roth, Rebecca Warner); Dallas, (James Cutrell, Roger Bedimo, John Battaile, Teagan Lampkin, Joyce Ghormley, David Albracht, Cyenthia Willis, Padmashri Rastogi, Holly Wise); Gainesville, (Peruvemba Sriram, Omerea Herring, Daniel Urbine, James Wynne, Ramanjeet Singh, Alice Boyette, Rosie Kizza, Eloise Harman, Michelle Ginsburg); Houston, (Charlie Lan, Sarah Perusich, Daniel Musher, Farrah Kheradmand, Lavannya Pandit, Roberto Casal, Rolando Rumbaut, Amir Sharafkhaneh, Suryakanta Velamuri, Pamela Smithwick, Sherilyn Pillack, Nazanin Zarinkamar, Emily Broussard, Cynthia Boudreaux); Indianapolis, (John Callaghan, Sharon Henson, Casey Stahlheber, Vru Patel, Aliya Noor); Kansas City, (Mark Plautz, Cheryl Perkins, Trenton Nauser, Justine Unruh); Lexington, (Takako Schaninger, Edward Hirshowitz, Hannah Ferrell, Sabrina Broden); Loma Linda, (Lennard Specht, Laura Weaver-Carnahan,

James Anholm, Hemad Parekh, Nagamani Dandamudi, Kathleen Ellstrom, Jamie Portillo, Sara Rubio); Long Beach, (Catherine Sassoon, Romena Helal, Yih-Ming Chi, Farhad Mazdisnian, Aliya Asghar, David Stansbury, Gelincik Oraciklar, Lei Zhu); Louisville, (Juan Guardiola, Belica Graf, Rafael Perez, Bogdan Moldoveanu, Julio Ramirez, Jesse Roman, Umair Guahar, Angela Kain, Jinesh Mehta, Ginny Sciortino); Memphis, (Muthiah P. Muthiah, Kathleen Bockhold, Ibrahim Sultan-Ali, Amado Freire, Muhammad Zaman, Veronica Castillo, Margaret Sanders, Lori Sykes); Miami, (Roland Schein, Jacqueline Junco, Lisa Camacho, Cynthia Cely, Michael Hyre, Gregory McGrath, Daniel Coes, Devora Khan); Milwaukee, (Andreea Antonescu-Turcu, Susan Framberg, Mary Ellis, Sharon Pecsi, Christa Kallio); Minneapolis, (Kathryn Rice, Linda Kollman, Dennis Niewoehner, Angela Fabbrini, Debra Condon, Christine Wendt, Erin Wetherbee, Miranda Deconcini, Brandon Doyle, George Sarosi, Ken Kunisaki, Doris Stuber), Oklahoma, (Houssein Youness, Laurel Howard, Jean Keddissi, Ahmed Awab, Ashley Ellis); Omaha, (Lee Morrow, Mary Pote, Kristina Bailey, Daniel Hershberger, Theresa Ramelb); Palo Alto, (Ware Kuschner, Elena Nikolaev, Juliana Barr, Edward Bertaccini, Karen Bratcher, Carlos Brun, Rajinder Chitkara, Jon-Erik Holty, Geoffrey Lighthall, Daphne Ly, Harman Paintal, Craig Zone, Alda Vicencio); Phoenix, (Lilibeth Pineda, Susan Brannan, Clement Singarajah, Pat Jacobs, Lisa Orozco); Pittsburgh, (Sharon Camhi, Marie Berger, Kathryn Hartwig, Charles Atwood, Sarita Kumari, Emily Grum, Mary Van Buskirk, Marcia Homer, Melissa Clark); Providence, (Matthew Jankowich, Sandra Befera, Linda Nici, Sharon Rounds); Reno, (Waseem Ahmed, Anne Inda, Anurag Mehta, Pam Lehman, Andrew Liu, Claudine Aguilera); Salem, (Thomas Martin, Mary Halling, Anil Agarwal, David Boone, Barbara Bowers, Neeraj Gupta, Mitchell Horowitz, Deepa Lala, Mitra Sahebazamani, Tonda Yates); Salt Lake City, (John Nord, Amy Beckstead, Elisabeth Carr, Moises Cortez, Heather Dulin, Mark Elstad, Lydia Rosenthal, Karl Sanders, Lindsay Carpenter, Wade Brown); San Antonio, (Marcos Restrepo, Luis Reyes, Antonio Anzueto, Alejandro Arango, Sandra Adams, Anisha Arora, Karla Diaz, Felipe Fernandez, Pamela Foltz, Tim Hernandez, Timothy Houlihan, Stephanie Levine, Adriel Malave, Breion Mallioux, Diego Maselli, Benjamin Michels, Anoop Nambiar, Hector Payan, Jay Peters); San Diego, (Timothy Bigby*****, Keith Nicalo, Judd Landsberg, Mark Fuster, Philippe Montgrain, Danielle Beck), San Juan, (William Rodriguez-Cintron, Julia Roig, Damaris Acosta-Miranda, Edwin Alicea, Joan Albors-Sanchez, Jesse Aleman-Ortiz, Felicita Aruz, Onix Cantres-Fonseca, Maria del Mar Torres-Perez, Francisco Del Olmo, Juan Flores, Sandra Galarza-Vargas, Ricardo Hernandez-Castillo, Juancarlos Martinez, Carlos Robles-Arias, Yarilys Rodriguez-Sepulveda); Seattle, (Vincent Fan, Cynthia Lotane, Pauline Shull, Richard Goodman, Cornelia Schneider); Syracuse, (Pratibha Kaul, Autum Bellinger, Girish Trikha, Adnan Abbasi, Bonnie VerHeecke, Mark Chilton); Tucson, (Michael Habib, Tom Vincent, Gina Blackwell, Dena L'Heureux, Wei Shen); Washington DC , 887 (Nitin Seam, Parisa Coffman, Bashar Albarghuthy, Jessica Smith); West Los Angeles, 890 (Guy Soo Hoo, May Luciano).

Member of Committees and CSP 574 organizational structure of the trial

Planning Committee: Gianfranco Umberto Meduri, MD (Principal Proponent: Memphis VA Medical Center); Antonio Anzueto, MD (University of Texas Health Science Center); Mark Holodniy, MD (VA Palo

Alto Health Care System); Philip Lavori, PhD (Stanford Comprehensive Cancer Center); Linda Nichols, PhD (Memphis VA Medical Center); Lori Nielsen (VA Palo Alto Cooperative Studies Program Coordinating Center); Mei-Chiung Shih, PhD (VA Palo Alto Cooperative Studies Program Coordinating Center); Anthony F. Suffredini, MD (National Institutes of Health Clinical Center); Derek C. Angus, MD, MPH (University of Pittsburgh School of Medicine); Thomas M. File, Jr., MD, MSc (Northeastern Ohio Universities College of Medicine); Kelvin K. Lee, PhD (VA Palo Alto Cooperative Studies Program Coordinating Center); Paul Marik, MD (East Virginia Medical School); Dennis E. Niewoehner, MD (Minneapolis VA Healthcare System); Mike Sather, PhD (VA CSP Clinical Research Pharmacy Coordinating Center, Albuquerque, NM); Mark W. Smith, PhD (VA Health Economics Resource Center); Stuart R. Warren, JD, PharmD (VA CSP Clinical Research Pharmacy Coordinating Center, Albuquerque, NM).

Study Chairman's office: Gianfranco Umberto Meduri, MD (Memphis VA Medical Center); Lisa Bridges, RN, MS, ACNP-BC (Memphis VA Medical Center); Jennifer Ransom, MPH (Memphis VA Medical Center).

Executive Committee: Gianfranco Umberto Meduri, MD (Memphis VA Medical Center); Lisa Bridges, RN, MS, ACNP-BC (Memphis VA Medical Center); Ali El-Solh, MD (VA Western New York Health Care System); Nitin Seam, MD (National Institutes of Health Clinical Center); Antonio Anzueto, MD (University of Texas Health Science Center); Anthony F. Suffredini, MD (National Institutes of Health Clinical Center); Reba Umberger, MS, RN, CCRN, PhD (University of Tennessee Health Science Center); W. Andrew Bell, PharmD (Memphis VA Medical Center, Renown Health, Reno, NV); Anne Davis-Karim, PharmD and Stuart R. Warren, JD, (ex officio) (VA CSP Clinical Research Pharmacy Coordinating Center); Thomas J. Martin, MD (Salem VA Medical Center); Mei-Chiung Shih, PhD, Colleen Fitzsimmons, BS, Kelvin Lee, PhD, (ex officio), Julia Lin, PhD, (ex officio), Valerie McGuire, PhD, (ex officio), Lori Nielsen, BA, (ex officio) (VA CSP Palo Alto Coordinating Center).

Data and Safety Monitoring Committee: Robert Danner, MD (National Institutes of Health Clinical Center); Matthew Goetz, MD (VA Greater Los Angeles Healthcare System); Joan Hilton, ScD (University of California San Francisco); John Kellum, MD (University of Pittsburgh School of Medicine); David Looney, MD, PhD (University of California San Diego); Colin Wu, PhD (National Heart Lung and Blood Institute); Richard ZuWallack, MD (Saint Francis Hospital and Medical Center).

Clinical Evaluation Committee: Ali El-Solh, MD (VA Western New York Health Care System); Nitin Seam, MD (National Institutes of Health Clinical Center); Marcos Restrepo, MD (South Texas Veterans Health Care System); Antonio Anzueto, MD (University of Texas Health Science Center); Octavian Ioachimescu, MD (Atlanta VA Health Care System); Charlie Lan, MD (Michael E. DeBakey VA Medical Center).

VA Palo Alto CSP Coordinating Center: Mei-Chiung Shih, PhD, Ying Lu, PhD, Kelvin Lee, PhD, Valerie McGuire, PhD, Julia Lin, PhD, Lan Zhao, Colleen Fitzsimmons, Lori Nielsen, Parinaz Lajevardi, MPH, Aileen Baylosis, Elizabeth Smith, Lauren Uyeda, Ania Ray, Jennifer Cockroft, Martha Forrester, Aaron Alsleben, Anita Kelly, Nigel Gladhart.

VA Albuquerque CSP Clinical Research Pharmacy Coordinating Center: Stuart Warren, JD, PharmD, Anne Davis-Karim, PharmD, Alexandra Scrymgeour, PharmD, Jolene Day, David Pittman.

The CSP Site Monitoring, Auditing and Review Team (SMART); Mary Mills, RN, CCRA, Tasha Anderson, RN, BSN, Mariette Coyle, RN, MSN, Barbara Curtis, Michelle Prehoda, Clair Haakenson, Darlene Kreuger.

References

1. Mayr FB, Yende S, Angus DC, (2014) Epidemiology of severe sepsis. Virulence 5: 4-11
2. Kang C-I, Song J-H, Kim SH, Chung DR, Peck KR, Thamlikitkul V, Wang H, So TM-k, Hsueh P-R, Yasin RM, (2013) Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect 66: 34-40
3. Cillóniz C, Polverino E, Ewig S, Aliberti S, Gabarrús A, Menéndez R, Mensa J, Blasi F, Torres A, (2013) Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest 144: 999-1007
4. Hsu JL, Siroka AM, Smith MW, Holodniy M, Meduri GU, (2011) One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System. Int J Infect Dis 15: e382-387
5. Musher DM, Montoya R, Wanahita A, (2004) Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 39: 165-169
6. Corrales-Medina VF, Musher DM, (2011) Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect 63: 187-199
7. Iwashyna TJ, Ely EW, Smith DM, Langa KM, (2010) Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA : the journal of the American Medical Association 304: 1787-1794
8. Wang HE, Szychowski JM, Griffin R, Safford MM, Shapiro NI, Howard G, (2014) Long-term mortality after community-acquired sepsis: a longitudinal population-based cohort study. BMJ open 4: e004283
9. Confalonieri M, Meduri GU, (2011) Glucocorticoid treatment in community-acquired pneumonia. Lancet 377: 1982-1984
10. Yende S, Kellum JA, Talisa VB, Palmer OMP, Chang C-CH, Filbin MR, Shapiro NI, Hou PC, Venkat A, LoVecchio F, (2019) Long-term Host Immune Response Trajectories Among Hospitalized Patients With Sepsis. JAMA network open 2: e198686-e198686
11. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, Alexander PE, Fei Y, Vandvik PO, Loeb M, Guyatt GH, (2015) Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med 163: 519-528
12. Briel M, Spoorenberg SM, Snijders D, Torres A, Fernandez-Serrano S, Meduri GU, Gabarrús A, Blum CA, Confalonieri M, Kasenda B, (2017) Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. Clin Infect Dis 66: 346-354
13. Meduri GU, Chrousos GP, (2020) General Adaptation in Critical Illness: Glucocorticoid Receptor-alpha Master Regulator of Homeostatic Corrections. Front Endocrinol (Lausanne) 11
14. Nawab Q, Golden E, Confalonieri M, Umberger R, Meduri G, (2011) Corticosteroid treatment in severe community-acquired pneumonia: duration of treatment affects control of systemic inflammation and clinical improvement. Intensive care medicine 37: 1153-1554

15. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr., Musher DM, Niederman MS, Torres A, Whitney CG, (2007) Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2: S27-72
16. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL, (2008) Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34: 17-60
17. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL, (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286: 1754-1758
18. Kazis LE, Selim AJ, Rogers W, Ren XS, Lee A, Miller D, Veterans RAND 12 item Health Survey (VR-12): A white paper summary DOI
19. Selim AJ, Rogers W, Fleishman JA, Qian SX, Fincke BG, Rothendler JA, Kazis LE, (2009) Updated U.S. population standard for the Veterans RAND 12-item Health Survey (VR-12). Qual Life Res 18: 43-52
20. Lawton MP, Brody EM, (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179-186
21. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW, (1963) Studies of Illness in the Aged. The Index of Adl: A Standardized Measure of Biological and Psychosocial Function. JAMA 185: 914-919
22. Lai TL, Shih M-C, (2004) Power, sample size and adaptation considerations in the design of group sequential clinical trials. Biometrika 91: 507-528
23. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN, (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336: 243-250
24. Moreno RP, Metnitz PG, Almeida E, Jordan B, Bauer P, Campos RA, Iapichino G, Edbrooke D, Capuzzo M, Le Gall JR, (2005) SAPS 3--From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med 31: 1345-1355
25. Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, Wei LJ, (2012) Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. Clin Trials 9: 570-577
26. Pastores SM, Annane D, Rochwerg B, (2018) Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Medicine 44: 474-477
27. Briel M, Spoorenberg SMC, Snijders D, Torres A, Fernandez-Serrano S, Meduri GU, Gabarrus A, Blum CA, Confalonieri M, Kasenda B, Siemieniuk RAC, Boersma W, Bos WJW, Christ-Crain M, Ovidius Study G, Capisce Study G, Group SS, (2018) Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. Clin Infect Dis 66: 346-354

28. Coelho LM, Salluh JI, Soares M, Bozza FA, Verdeal JC, Castro-Faria-Neto HC, Lapa e Silva JR, Bozza PT, Povoa P, (2012) Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care 16: R53
29. Monedero P, Gea A, Castro P, Candela-Toha AM, Hernandez-Sanz ML, Arruti E, Villar J, Ferrando C, Network C-SI, (2021) Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study. Crit Care 25: 2
30. Meduri GU, Annane D, Confalonieri M, Chrousos GP, Rochwerg B, Busby A, Ruaro B, Meibohm B, (2020) Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Intensive Care Med 46: 2284-2296
31. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, Gabarrus A, Sellares J, Restrepo MI, Anzueto A, Niederman MS, Agusti C, (2015) Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response: A Randomized Clinical Trial. JAMA 313: 677-686
32. Rodriguez JM, Monsalves-Alvarez M, Henriquez S, Llanos MN, Troncoso R, (2016) Glucocorticoid resistance in chronic diseases. Steroids 115: 182-192
33. Cangemi R, Falcone M, Taliani G, Calvieri C, Tiseo G, Romiti GF, Bertazzoni G, Farcomeni A, Violi F, group Ss, (2019) Corticosteroid Use and Incident Myocardial Infarction in Adults Hospitalized for Community-Acquired Pneumonia. Ann Am Thorac Soc 16: 91–98
34. Annane D, Pastores S, Rochwerg B, Arlt W, Balk R, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper M, (2017) Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Critical Care Medicine 45: 2078-2088
35. Odeyemi YE, Herasevich S, Chalmers SJ, Barreto EF, Frank RD, Gajic OO, Yadav H, (2020) Biomarker-Concordant Steroid Use in Critically Ill Patients with Pneumonia. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 4: 649-656
36. Li J, Liao X, Zhou Y, Wang L, Yang H, Zhang W, Zhang Z, Kang Y, (2021) Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis. Shock 56: 215-228
37. Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ, (2021) Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 384: 693-704
38. World Health Organization (2020) Corticosteroids for COVID-19: living guidance, 2 September 2020. In: Editor (ed)^(eds) Book Corticosteroids for COVID-19: living guidance, 2 September 2020. World Health Organization, City, pp.
39. Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler JA, Aguilar G, Alba F, Gonzalez-Higueras E, Conesa LA, Martin-Rodriguez C, Diaz-Dominguez FJ, Serna-Grande P, Rivas R, Ferreres J, Belda J, Capilla L, Tallet A, Anon JM, Fernandez RL, Gonzalez-Martin JM, dexamethasone in An, (2020) Dexamethasone treatment for the acute

respiratory distress syndrome: a multicentre, randomised controlled trial. The Lancet Respiratory medicine 8: 267-276

40. Yates CR, Vysokanov A, Mukherjee A, Ludden TM, Tolley EA, Meduri GU, Dalton JT, (2001) Time-variant increase in methylprednisolone clearance in patients with acute respiratory distress syndrome: A population pharmocokinetic study. J Clin Pharmacol 41: 1-10

41. Chriguer RS, Elias LLK, da Silva Jr IM, Vieira JGH, Moreira AC, de Castro M, (2005) Glucocorticoid sensitivity in young healthy individuals: in vitro and in vivo studies. The Journal of Clinical Endocrinology & Metabolism 90: 5978-5984

Figures

Figure 1. Enrollment, Randomization and Follow-up.

Figure 2. Kaplan-Meier Estimate of Survival.

Kaplan-Meier estimates of survival are shown in the overall population (Panel A), in patients who were receiving mechanical ventilation at randomization (Patients on MV; Panel B), and in those not receiving mechanical ventilation at randomization (Patients not on MV; Panel C). The inset in each panel shows the same data on an enlarged y axis and up to Day 60.

Figure 3. 60-day all-cause mortality according to subgroup.

The odds ratios and 95% confidence intervals are based on logistic regression with treatment as the single covariate. The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects.

Figure 1.


Assessed for eligibility (n=3936) ¥
Did not meet inclusion criteria (n =905) §
Not in hospital (n=30)
Failed to meet severe CAP/HCAP (n=830)
Exceeded enrollment time window (n=70)
Protocol Deviation (n=3)
Met exclusion criteria (n=1996) §
Physician felt patient not viable study candidate (n=577)
Glucocorticoid medication (n=255)
COPD with acute exacerbation requiring glucocorticoid treatment (n=610)
History of aspiration of gastric content (n=183)
Fatal preexisting medical condition (n=202)
Severe immunosuppression (n=253)
Severe cognitive impairment (n=227)
Declined participation (n =450)
Other (n=6)
Randomized (n =584) §
Methylprednisolone (n =297)
Received allocated study drug (n =293)
Did not receive allocated study drug (n=4)
Study drug withdrawal (n=64)*
Active gastrointestinal bleeding (n=2) ¶
Conditions requiring prolonged glucocorticoid administration (n=14) ¶¶
Family or participant request (n=23)
Withdrawal of all support care (n=7)
Related to SAEs (n=5)
Placebo (n =287)
Received allocated study drug (n = 282)
Did not receive allocated study drug (n = 5)
Study drug withdrawal (n=63)*
Active gastrointestinal bleeding (n=1) ¶
Conditions requiring prolonged glucocorticoid administration (n=17) ¶¶
Family or participant request (n=24)
Withdrawal of all support care (n=6)
Related to SAEs (n=8)
Physician withdrawal based on other clinical concerns (n=11)
Other (n=9)
Completed follow-up:
Day 28 (n=243)
Day 60 (n=235)
Day 180 (n=216)
One year (n=180)
Early termination from study (n=117)
Death (n=78)
Study ended early (n=26)
Patient withdrew consent (n=8)
Patient withdrawn by physician (n=1)
Patient withdrawn by LAR/DPOA (n=4)
Completed follow-up:
Day 28 (n=228)
Day 60 (n=221)
Day 180 (n=202)
One year (n=169)
Early termination from study (n=118)
Death (n=83)
Study ended early (n=23)
Patient withdrew consent (n=10)
Patient withdrawn by site (n=1)
Could not be contacted (n=1)
¥
Analyzed (n=297)
Analyzed (n=287)

Participants who were consented improperly are not included in this diagram.

§ The reasons for failing eligibility criteria were "select all that apply," so one patient may have more than one reason for exclusion. Five patients who did not meet eligibility criteria (three did not meet inclusion criteria and two met exclusion criteria) were randomized.
* Reasons for study drug withdrawal were check all that apply.
¶ Active gastrointestinal bleeding requiring transfusion of at least 5 units of PRBC's.
¶¶ Such as exacerbation of COPD or asthma, vasculitis.

Figure 2.



No. at Risk

Methylprednisolone	297	247	239	234	231	226	220	211	208	205	199	190	180
Placebo	287	240	227	222	220	214	209	200	195	188	181	176	169

B Patients in MV



No. at Risk													
Methylprednisolone	97	75	72	70	69	67	67	66	66	65	62	59	54
Placebo	96	78	70	69	67	66	66	65	62	58	57	56	55

C Patients in Non-MV



No. at Risk													
Methylprednisolone	200	172	167	164	162	159	153	145	142	140	137	131	126
Placebo	191	162	157	153	153	148	143	135	133	130	124	120	114

Figure 3.


Subgroup
No. of Patients
No. of Deaths
Odds Ratio (95% CI)
Overall 563 97 0.89 (0.58, 1.38)
MV status at randomization
MV 188 46 0.89 (0.46, 1.73)
Non-MV 375 51 0.90 (0.50, 1.63)
APACHE III score quartiles
Q1 144 18 0.70 (0.26, 1.90)
Q2 134 13 0.93 (0.30, 2.93)
Q3 144 18 0.59 (0.21, 1.66)
Q4 140 47 0.89 (0.44, 1.82)
HCAP
Yes 196 43 0.85 (0.43, 1.68)
No 367 54 0.86 (0.48, 1.53)
0.1
0.5
1
1.5
2
2.5
3
3.5
Methyprednisolone Better
Placebo Better

List of Tables:

Table 1. Baseline characteristics

Characteristic	Methylprednisolone (n=297)	Placebo (n=287)
Age - years	69.0 ± 10.8	68.6 ± 11.1
Male sex – no./total no. (%)	289/297 (97%)	273/286 (95%)
Ethnicity – no./total no. (%)		
Not Spanish, Hispanic or Latino	255/286 (89%)	251/280 (90%)
Mexican, Mexican American, or Chicano	16/286 (6%)	12/280 (4%)
Puerto Rican	5/286 (2%)	8/280 (3%)
Cuban	0 (0%)	1/280 (0%)
Other Spanish, Hispanic or Latino	10/286 (3%)	8/280 (3%)
Race – no./total no. (%)		
White	245/287 (85%)	227/281 (81%)
Black/African American	36/287 (13%)	48/281 (17%)
Other	15/287 (5%)	10/281 (4%)
BMI ≥ 30 – no./total no. (%)	62/297 (21%)	70/285 (25%)
Smoking status – no./total no. (%)		
Current smoker	98/294 (33%)	89/284 (31%)
Prior smoker (not current smoker)	155/294 (53%)	139/284 (49%)
Lifetime non-smoker	41/294 (14%)	56/284 (20%)
Any major comorbidity – no./total no. (%)	290/297 (98%)	275/285 (96%)
No. of major comorbidities	4.0 ± 1.8	3.9 ± 1.9
Charlson Comorbidity Index	5.77 ± 2.39	5.65 ± 2.24
ACE27 Overall Comorbidity Score – no./total no. (%)		
0	6/297 (2%)	8/285 (3%)
1	38/297 (13%)	33/285 (12%)
2	51/297 (17%)	59/285 (21%)
3	202/297 (68%)	185/285 (65%)
ACE27 Total Score	2.51 ± 0.79	2.48 ± 0.81
Karnofsky Performance Score	72.4 ± 22.0	72.9 ± 22.4

Characteristic	Methylprednisolone (n=297)	Placebo (n=287)
Health Care-Associated Pneumonia (HCAP) – no./total no. (%)	112/297 (38%)	89/287 (31%)
Resided in nursing home or long-term care facility immediately prior to hospital admission	40/297 (13%)	48/287 (17%)
Hospitalized in acute care hospital for two or more days within past 90 days	81/297 (27%)	58/287 (20%)
Received intravenous therapy (antibiotic or chemotherapy) within past 30 days	42/297 (14%)	31/287 (11%)
Received home wound care within past 30 days	18/297 (6%)	13/287 (5%)
Received hemodialysis within past 30 days	10/297 (3%)	8/287 (3%)
Admission from the ward – no. (%)	66/297 (22%)	57/287 (20%)
Time from hospital admission to randomization – days, median (IQR)	1.7 (1.0-2.2)	1.4 (0.9-2.0)
Pneumonia Severity Index (PSI)	125.6 ± 37.2	122.3 ± 34.4
PSI class – no. (%)		
I	3/297 (1%)	4/285 (1%)
II	13/297 (4%)	13/285 (5%)
III	41/297 (14%)	29/285 (10%)
IV	121/297 (41%)	126/285 (44%)
V	119/297 (40%)	113/285 (40%)
PIRO	2.14 ± 1.12	2.15 ± 1.10
CURB-65	2.69 ± 1.03	2.59 ± 1.03
Chest Radiograph Score	2.09 ± 1.02	1.94 ± 1.08
Bilateral – no./total no. (%)	189/288(66%)	163/276 (59%)
Multilobar – no./total no. (%)	216/297 (73%)	188/285 (66%)
PaO2:FiO2 (if PaO2 is available) [a]	181 ± 85	188 ± 90
SpO2:FiO2 (if PaO2 is not available) [b]	283 ± 101	286 ± 98
ALI-ARDS at randomization – no./total no. (%)	26/297 (9%)	39/285 (14%)
Bacteremia – no./total no. (%)	49/282 (17%)	32/275 (12%)
White Blood Cell Count (x10^6cells/mL)	15.25 ± 12.44	14.55 ± 7.23
APACHE III Score	54.3 ± 29.4	53.4 ± 28.7

Characteristic	Methylprednisolone (n=297)	Placebo (n=287)
SAPs III Score	59.4 ± 10.7	58.5 ± 9.9
SOFA Score	6.68 ± 3.00	6.29 ± 2.85
Lactate Level (mmol/L)[c]	1.84 ± 1.25	1.82 ± 1.81
Mechanical Ventilation (MV) at Study Entry – no. / total no. (%)	97/297 (33%)	96/287 (33%)
Vasopressor Dependent Shock at or prior to study entry – no. / total no. (%)	44/296 (15%)	32/285 (11%)
Use of anti-inflammatory medications at baseline – no. / total no. (%)[d]	241/297 (81%)	221/286 (77%)
Use of macrolide antibiotics at baseline – no./total no. (%)	64/297 (22%)	52/286 (18%)
Antibiotic treatment in the participants who were not admitted from other hospital - no. / total no. (%)[e]		
Did not receive initial antibiotics	34/278 (12%)	34/271 (13%)
Received initial antibiotics within 6 hours of hospital admission	232/278 (83%)	222/271 (82%)
Received initial antibiotics beyond 6 hours of hospital admission	11/278 (4%)	9/271 (3%)
Unknown	1/278 (0%)	6/271 (2%)
Adequate initial antibiotic treatment based on guidelines[f] – no. / total no. (%)	286/293 (98%)	265/278 (95%)
Tested for Influenza – no. / total no. (%)	182/294 (62%)	173/277 (62%)
Tested positive for influenza in participants who were tested for influenza – no. / total no. (%)	14/144 (10%)	11/131 (8%)
Tested positive for both influenza and bacteria – no. / total no. (%)	7/297 (2%)	6/287 (2%)

[a] 379 participants had a PaO2:FiO2 measurement (201 in the methylprednisolone group, 178 in the placebo group).
[b] 167 participants had an SpO2:FiO2 measurement (79 in the methylprednisolone group, 88 in the placebo group).
[c] 514 participants had a Lactate Level measurement (261 in the methylprednisolone group, 253 in the placebo group).
[d] 240 (41%) participants used aspirin at baseline (122 in the methylprednisolone group, 118 in the placebo group); and 58 (10%) participants used systemic corticosteroids (31 in methylprednisolone, 27 in placebo).
[e] Excludes one participant with time to initial antibiotic treatment from hospital admission longer than 700 hours. This value was mostly likely due to a data entry error.
[f] Excludes participants who did not receive antibiotics within 6 hours of hospital admission.

Table 2. Primary and Secondary Outcomes.

Outcome	Methylprednisolone (n=297)	Placebo (n=287)	Difference[a] (95% CI)	P-value[b]
Primary Outcome				
Died on or prior to study day 60 – no. / total no. (%)	47/286 (16%)	50/277 (18%)	0.89 (0.58, 1.38)[c]	0.61
Secondary Outcomes				
In-hospital morbidity and mortality				
Vasopressor dependent shock during initial hospital stay among those who did not have vasopressor dependent shock at randomization – no. / total no. (%)	13/274 (5%)	12/271 (4%)	1.08 (0.48, 2.40)[d]	1.00
ALI-ARDS during initial hospital stay among those who did not have ALI-ARDS at randomization – no. / total no. (%)	10/265 (4%)	8/241 (3%)	1.14 (0.44, 2.94)[d]	1.00
MODS-free days in study days 1-8 – median (IQR) and no./total no. (%)	0 (0 - 0)	0 (0 - 0)	NE	0.38
0	249/288 (86%)	252/275 (92%)		
1	5/288 (2%)	10/275 (4%)		
2	4/288 (1%)	4/275 (1%)		
3	4/288 (1%)	2/275 (1%)		
4	3/288 (1%)	2/275 (1%)		
5	3/288 (1%)	0/275 (0%)		
6	0/288 (0%)	1/275 (0%)		
7	12/288 (4%)	2/275 (1%)		
8	8/288 (3%)	2/275 (1%)		
MV-free days in study days 1-8 – median (IQR)	8 (4 - 8)	8 (3 - 8)	0 (-0.4, 0.4)	1.00
MV-free days in study days 1-28[e] – median (IQR)	28 (23 - 28)	28 (21 - 28)	0 (-0.6, 0.6)	1.00
MV-free days in study days 1-8 in the MV stratum – median (IQR)	4 (0 - 7)	1 (0 - 6)	3 (1.1, 4.9)	0.66

Outcome	Methylprednisolone (n=297)	Placebo (n=287)	Difference[a] (95% CI)	P-value[b]
MV-free days in study days 1-28 in the MV stratum[e] – median (IQR)	23 (13 - 27)	21 (0 - 26)	2 (-0.8, 4.8)	1.00
Duration of initial ICU stay (from day 0)[f] – median (IQR)	3 (2 - 7)	4 (2 - 7)	-1 (-1.7, -0.3)	1.00
Duration of total ICU stay up to study day 28 (from day 0)[f] – median (IQR)	3 (2 - 8)	4 (2 - 8)	-1 (-1.7, -0.3)	1.00
Duration of initial hospital stay (from day 0)[f] – median (IQR)	7 (4 - 12)	8 (4 - 15)	-1.0 (-2.3, 0.3)	1.00
Hospital Mortality – no. / total no. (%)	34/291 (12%)	28/281 (10%)	1.20 (0.70, 2.03)[g]	1.00
Post-discharge morbidity and mortality				
Cardiovascular complications[h] – no. / total no. (%)				
Up to Day 28	11/251 (4%)	12/234 (5%)	0.85 (0.37 - 1.96)	1.00
Up to Day 60	18/257 (7%)	17/250 (7%)	1.03 (0.52 - 2.05)	1.00
Up to Day 180	31/257 (12%)	30/253 (12%)	1.02 (0.60 - 1.74)	1.00
VR-12 Physical Component Score[i]				
Day 28	37.5 ± 14.0	37.2 ± 13.8	0.2 (-2.6, 3.0)	1.00
Day 60	38.8 ± 15.3	40.3 ± 14.5	-1.5 (-4.5, 1.5)	1.00
Day 180	41.2 ± 14.9	40.8 ± 15.7	0.4 (-3.0, 3.8)	1.00
VR-12 Mental Component Score[i]				
Day 28	32.7 ± 9.6	33.9 ± 9.3	-1.2 (-3.2, 0.7)	1.00
Day 60	32.4 ± 8.9	32.0 ± 9.0	0.4 (-1.4, 2.2)	1.00
Day 180	31.5 ± 8.2	32.8 ± 9.2	-1.3 (-3.2, 0.6)	1.00
Katz ADL[i]				
Day 28	4.99 ± 1.84	4.74 ± 2.07	0.25 (-0.14, 0.64)	1.00
Day 60	5.11 ± 1.71	5.03 ± 1.81	0.08 (-0.27, 0.43)	1.00
Day 180	5.12 ± 1.66	5.02 ± 1.85	0.10 (-0.29, 0.48)	1.00
Lawton IADL[i]				
Day 28	5.39 ± 2.61	5.30 ± 2.72	0.09 (-0.45, 0.62)	1.00

Outcome	Methylprednisolone (n=297)	Placebo (n=287)	Difference[a] (95% CI)	P-value[b]
Day 60	5.42 ± 2.62	5.71 ± 2.63	-0.29 (-0.82, 0.24)	1.00
Day 180	5.77 ± 2.57	5.96 ± 2.60	-0.19 (-0.76, 0.38)	1.00
Any rehospitalization within 12 months [j] - no. / total no. (%)	135/253 (53%)	120/250 (48%)	1.24 (0.87, 1.76)[g]	1.00
Number of rehospitalizations within 12 months [k] - median (IQR)	1 (1 - 3)	2 (1 - 3)	-1 (-1.4, -0.6)	1.00
Died by study day 180 - no. / total no. (%)	59/279 (21%)	65/274 (24%)	0.86 (0.58, 1.29)[g]	1.00
Restricted mean survival time up to day 180 – RMST (SE)	151.5 (3.6)	149.0 (3.7)	2.5 (-7.7, 12.6)[l]	1.00
Died by 1 year - no. / total no. (%)	79/260 (30%)	84/253 (33%)	0.88 (0.61, 1.27)[g]	1.00
Time to death (days) – no. / total no. (%)	79/297 (27%)	84/287 (29%)	0.90 (0.66, 1.22)[g]	1.00
Exploratory Outcome				
Duration of MV up to day 28 in the participants who were on MV at randomization – median (IQR) [m]	4 (1 - 9)	7 (2 - 27)	1.4 (1.0, 2.0)	0.21

[a] Difference between treatment group is expressed as: odds ratio for binary variables; difference in medians for MV-free days up to day 8 and day 28, duration of ICU stay, total ICU days up to day 28, duration of initial hospital stay, and number of rehospitalizations within 12 months; difference in means for other continuous variables; hazards ratio for time to event variables. NE: The difference in median and the 95%CI could not be estimated because majority of the observed values were at the one end of the distribution.
[b] The P-values for secondary and exploratory outcomes are adjusted for multiplicity by Bonferroni correction (for 12 in-hospital outcomes and 21 post-discharge outcomes). The widths of the confidence intervals for the treatment differences in secondary and exploratory outcomes have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects.
[c] The adjusted odds ratio for 60-day mortality is 0.90 (95%CI, 0.57 - 1.40; p=0.63) when adjusted for site and mechanical ventilation status at randomization, and is 0.87 (95%CI, 0.53 – 1.42; p=0.58) when adjusted for site, mechanical ventilation status at randomization, age, APACHE III score, CCI, bacteremia, use of anti-inflammatory medications at baseline and use of macrolide at baseline. The unadjusted absolute risk difference in the 60-day mortality is -2% (95%CI, -8% to 5%).
[d] The unadjusted absolute risk difference is 0% (95%CI, -3% to 4%) for vasopressor dependent shock, and 0% (95%CI, -3% to 4%) for ALI-ARDS.
[e] MV-free days from Days 1-28 was calculated in 558 participants (287 in the methylprednisolone group and 271 in the placebo group). In the MV stratum, MV-free days from Days 1-28 was calculated in 181 participants (92 in the methylprednisolone group, 89 in the placebo group).
[f] The number of participants for whom the outcome was calculated in the methylprednisolone and placebo groups was, respectively, duration of initial ICU stay: 295 and 281; duration of total ICU stay up to Day 28: 291 and 280; duration of initial hospital stay: 291 and 281.
[g] The unadjusted methylprednisolone versus placebo absolute risk difference is 2% (95%CI, -3% to 7%) for hospital mortality, 5% (95%CI, -3% to 14%) for rehospitalization within 12 months, -3% (95%CI, -10% to 4%) for 180-day mortality, -3% (95%CI, -11% to 5%) for one-year mortality, and -3% (95%CI, -10% to 5%) for mortality over the study period.

[h] Cardiovascular complications included acute myocardial infarction, serious arrhythmias, new congestive heart failure or acute worsening of long-term congestive heart failure, and cardo-respiratory arrest.
[i] The number of participants for whom the VR-12 Physical Component Score (PCS) and Mental Component Score (MCS) was calculated at Day 28, 60 and 180 was: 197, 201 and 166 in the methylprednisolone group and 184, 177 and 148 in the placebo group. The number of participants for whom the Katz Activities of Daily Living (ADL) score was calculated at Day 28, 60 and 180 was: 203, 203 and 172 in the methylprednisolone group and 187, 180 and 150 in the placebo group. The number of participants for whom the Lawton Instrumental Activities of Daily Living (IADL) score was calculated at Day 28, 60 and 180 was: 202, 201 and 169 in the methylprednisolone group and 187, 180 and 149 in the placebo group.
[j] Among the 510 participants (257 in methylprednisolone group, 253 in placebo group) who were discharged alive from initial hospitalization. Seven of the 510 participants had missing rehospitalization data (4 in methylprednisolone group, 3 in placebo group) and were excluded from analysis.
[k] Among the 255 patients (135 in methylprednisolone group, 120 in placebo group) who had at least one rehospitalization within 12 months.
[l] The estimated difference in RMST up to study day 180, adjusted for MV status at randomization in a RMST regression using pseudovalue method, is 2.3 (95% CI -7.8 to 12.4), p-value adjusted for multiplicity =1.00.
[m] Participants who died on MV on or prior to day 28 were censored on day 29. 185 participants were included in this analysis (91 in the methylprednisolone group, 94 in the placebo group).

Supplemental Tables

Table S1. Baseline Comorbidities.

All participants	**Methylprednisolone (n=297)**	**Placebo (n=285)**
Any major co-morbidities – no./total no. (%)	290/297 (98%)	275/285 (96%)
No. of major comorbidities	4.0 ± 1.8	3.9 ± 1.9
Major comorbidity		
Diabetes Mellitus	148/297 (50%)	130/285 (46%)
Hypertension	236/297 (79%)	218/285 (76%)
Dyslipidemia	167/297 (56%)	164/285 (58%)
Obesity	62/297 (21%)	70/285 (25%)
Atherosclerotic cardiovascular disease	134/297 (45%)	107/285 (38%)
Congestive heart failure	72/297 (24%)	54/285 (19%)
Chronic obstructive lung disease	129/297 (43%)	135/285 (47%)
Chronic liver disease	25/297 (8%)	25/285 (9%)
Chronic renal insufficiency	35/297 (12%)	35/285 (12%)
Malignancy or immunocompromised	55/297 (19%)	52/285 (18%)
Alcohol abuse	21/297 (7%)	28/285 (10%)
Illicit drug abuse	11/297 (4%)	9/285 (3%)
Depression or bipolar disorder	89/297 (30%)	98/285 (34%)
MV Stratum	**Methylprednisolone (n=97)**	**Placebo (n=96)**
Any major comorbidity – no./total no. (%)	95/97 (98%)	91/96 (95%)
No. of major comorbidities	4 ± 1.8	3.8 ± 2.0
Major comorbidity		
Diabetes Mellitus	49/97 (51%)	48/96 (50%)
Hypertension	73/97 (75%)	71/96 (74%)
Dyslipidemia	56/97 (58%)	54/96 (56%)
Obesity	25/97 (26%)	29/96 (30%)
Atherosclerotic cardiovascular disease	39/97 (40%)	32/96 (33%)

Congestive heart failure	24/97 (25%)	19/96 (20%)
Chronic obstructive lung disease	40/97 (41%)	37/96 (39%)
Chronic liver disease	7/97 (7%)	10/96 (10%)
Chronic renal insufficiency	10/97 (10%)	11/96 (11%)
Malignancy or immunocompromised	18/97 (19%)	15/96 (16%)
Alcohol abuse	11/97 (11%)	13/96 (14%)
Illicit drug abuse	4/97 (4%)	2/96 (2%)
Depression or bipolar disorder	31/97 (32%)	25/96 (26%)
Non-MV Stratum	**Methylprednisolone (n=200)**	**Placebo (n=189)**
Any major comorbidity – no./total no. (%)	195/200 (98%)	184/189 (97%)
No. of major comorbidities	4 ± 1.7	4 ± 1.8
Major comorbidity		
Diabetes Mellitus	99/200 (50%)	82/189 (43%)
Hypertension	163/200 (82%)	147/189 (78%)
Dyslipidemia	111/200 (56%)	110/189 (58%)
Obesity	37/200 (19%)	41/189 (22%)
Atherosclerotic cardiovascular disease	95/200 (48%)	75/189 (40%)
Congestive heart failure	48/200 (24%)	35/189 (19%)
Chronic obstructive lung disease	89/200 (45%)	98/189 (52%)
Chronic liver disease	18/200 (9%)	15/189 (8%)
Chronic renal insufficiency	25/200 (13%)	24/189 (13%)
Malignancy or immunocompromised	37/200 (19%)	37/189 (20%)
Alcohol abuse	10/200 (5%)	15/189 (8%)
Illicit drug abuse	7/200 (4%)	7/189 (4%)
Depression or bipolar disorder	58/200 (29%)	73/189 (39%)

Table S2. Primary and Secondary Outcomes – Per Protocol Analysis

Outcome	Methylprednisolone (n=243)	Placebo (n=243)	Difference[a] (95% CI)	P-value[b]
Primary Outcome				
Died on or prior to study day 60 – no. / total no. (%)	37/242 (15%)	39/240 (16%)	0.93 (0.57, 1.52) [c]	0.77
Secondary Outcomes				
In-hospital morbidity and mortality				
Vasopressor dependent shock during initial hospital stay among those who did not have vasopressor dependent shock at randomization – no. / total no. (%)	11/228 (5%)	10/234 (4%)	1.14 (0.47, 2.73) [d]	1.00
ALI-ARDS during initial hospital stay among those who did not have ALI-ARDS at randomization – no. / total no. (%)	6/220 (3%)	4/207 (2%)	1.42 (0.40, 5.12) [d]	1.00
MODS-free days in study days 1-8 - median (IQR) and no./total no. (%)	0 (0 - 0)	0 (0 - 0)	NE	0.71
0	209/243 (86%)	221/243 (91%)		
1	4/243 (2%)	9/243 (4%)		
2	4/243 (2%)	4/243 (2%)		
3	4/243 (2%)	2/243 (1%)		
4	2/243 (1%)	2/243 (1%)		
5	3/243 (1%)	0/243 (0%)		
6	0/243 (0%)	1/243 (0%)		
7	10/243 (4%)	2/243 (1%)		
8	7/243 (3%)	2/243 (1%)		
MV-free days from day 1 to day 8 – median (IQR)	8 (4 - 8)	8 (3 - 8)	0 (-0.4, 0.4)	1.00
MV-free days in study days 1-28 [e] - median (IQR)	28 (23 - 28)	28 (21 - 28)	0 (-0.6, 0.6)	1.00
MV-free days from day 1 to day 8 in the MV stratum – median (IQR)	4 (0 - 7)	1 (0 - 6)	3.0 (1.1, 4.9)	0.19
MV-free days in study days 1-28 in the MV stratum [e] – median (IQR)	23 (18 - 27)	21 (0 - 26)	2.0 (-4.1, 8.1)	1.00

Outcome	Methylprednisolone (n=243)	Placebo (n=243)	Difference[a] (95% CI)	P-value[b]
Duration of initial ICU stay (from day 0) [f] - median (IQR)	3 (2 - 7)	4 (2 - 8)	-1.0 (-1.9, -0.1)	1.00
Duration of total ICU stay up to study day 28 (from day 0) [f] - median (IQR)	3 (2 - 7)	4 (2 - 8)	-1.0 (-1.9, -0.1)	1.00
Duration of initial hospital stay (from day 0) [f] - median (IQR)	7 (4 - 12)	8 (4 - 15)	-1.0 (-2.5, 0.5)	1.00
Hospital Mortality – no. / total no. (%)	29/243 (12%)	23/242 (10%)	1.29 (0.72, 2.30) [g]	1.00
Post-discharge morbidity and mortality				
Cardiovascular complications [h] – no. / total no. (%)				
Up to Day 28	8/210 (4%)	10/201 (5%)	0.76 (0.29 - 1.96)	1.00
Up to Day 60	13/214 (6%)	15/216 (7%)	0.87 (0.40 - 1.87)	1.00
Up to Day 180	26/214 (12%)	26/219 (12%)	1.03 (0.58 - 1.83)	1.00
VR-12 Physical Component Score [i]				
Day 28	38.2 ± 13.7	37.7 ± 13.7	0.4 (-2.5, 3.4)	1.00
Day 60	38.8 ± 15.3	40.7 ± 14.5	-1.8 (-5.1, 1.4)	1.00
Day 180	41.2 ± 15.2	41.2 ± 15.6	0.0 (-3.6, 3.6)	1.00
VR-12 Mental Component Score [i]				
Day 28	32.0 ± 9.4	33.6 ± 9.4	-1.5 (-3.5, 0.5)	1.00
Day 60	32.7 ± 8.9	31.7 ± 8.7	1.0 (-0.9, 2.8)	1.00
Day 180	31.7 ± 8.4	32.7 ± 9.1	-1.0 (-3.1, 1.1)	1.00
Katz ADL [i]				
Day 28	4.99 ± 1.85	4.78 ± 2.06	0.21 (-0.20, 0.62)	1.00
Day 60	5.07 ± 1.75	4.96 ± 1.87	0.12 (-0.27, 0.50)	1.00
Day 180	5.12 ± 1.69	4.97 ± 1.88	0.15 (-0.27, 0.56)	1.00
Lawton IADL [i]				
Day 28	5.42 ± 2.62	5.36 ± 2.70	0.06 (-0.51, 0.62)	1.00
Day 60	5.46 ± 2.66	5.63 ± 2.71	-0.17 (-0.75, 0.40)	1.00
Day 180	5.77 ± 2.62	5.92 ± 2.68	-0.15 (-0.77, 0.47)	1.00

Outcome	Methylprednisolone (n=243)	Placebo (n=243)	Difference[a] (95% CI)	P-value[b]
Any rehospitalization within 12 months [j] - no. / total no. (%)	115/213 (54%)	103/218 (47%)	1.31 (0.90, 1.91) [g]	1.00
Number of rehospitalizations (by participant) within 12 months - median (IQR) [k]	1 (1 - 3)	2 (1 - 3)	-1 (-1.4126, -0.5874)	1.00
Died by study day 180 - no. / total no. (%)	48/236 (20%)	51/237 (22%)	0.93 (0.60, 1.45) [g]	1.00
Restricted mean survival time up to day 180 – RMST (SE)	152.4 (3.9)	151.8 (3.9)	0.7 (-10.1, 11.4) [l]	1.00
Died by 1 year - no. / total no. (%)	66/222 (30%)	67/216 (31%)	0.94 (0.63, 1.41) [g]	1.00
Time to death (days) – no. / total no. (%)	66/243 (27%)	67/243 (28%)	0.97 (0.69, 1.37) [g]	1.00
Exploratory Outcome				
Duration of MV up to day 28 in the participants who were on MV at randomization [m] – median (IQR)	4 (1 – 8)	7 (2 - 28)	1.6 (1.1, 2.2)	0.09

[a] Difference between treatment group is expressed as: odds ratio for binary variables; difference in medians for MV-free days up to day 8 and day 28, duration of ICU stay, total ICU days up to day 28, duration of initial hospital stay, and number of rehospitalizations within 12 months; difference in means for other continuous variables; hazards ratio for time to event variables. NE: The difference in median and the 95%CI could not be estimated because majority of the observed values were at the one end of the distribution.
[b] The P-values for secondary and exploratory outcomes are adjusted for multiplicity by Bonferroni correction (for 12 in-hospital outcomes and 21 post-discharge outcomes). The widths of the confidence intervals for the treatment differences in secondary and exploratory outcomes have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects.
[c] The adjusted odds ratio for 60-day mortality is 0.97 (95%CI, 0.58 - 1.60; p=0.89) when adjusted for site and mechanical ventilation status at randomization, and is 0.86 (95%CI, 0.49 – 1.53; p=0.61) when adjusted for site, mechanical ventilation status at randomization, age, APACHE III score, CCI, bacteremia, use of anti-inflammatory medications at baseline and use of macrolide at baseline. The unadjusted absolute risk difference in the 60-day mortality is -1% (95%CI, -7% to 6%).
[d] The unadjusted absolute risk difference is 1% (95%CI, -3% to 4%) for vasopressor dependent shock, and 1% (95%CI, -2% to 4%) for ALI-ARDS.
[e] MV-free days from Days 1-28 was calculated for 473 participants (239 in the methylprednisolone group, 234 in the placebo group). In the MV stratum, MV-free days from Days 1-28 was calculated for 157 participants (75 in the methylprednisolone group, 82 in the placebo group).
[f] The number of participants for whom the outcome was calculated in the methylprednisolone and placebo groups was, respectively, duration of initial ICU stay: 243 and 242; duration of total ICU stay up to Day 28: 243 and 242; duration of initial hospital stay: 243 and 242.
[g] The unadjusted methylprednisolone versus placebo absolute risk difference is 2% (95%CI, -3% to 8%) for hospital mortality, 7% (95%CI, -3% to 16%) for rehospitalization within 12 months, -1% (95%CI, -9% to 6%) for 180-day mortality, -1% (95%CI, -10% to 7%) for one-year mortality, and 0% (95%CI, -8% to 8%) for mortality over the study period.
[h] Cardiovascular complications included acute myocardial infarction, serious arrhythmias, new congestive heart failure or acute worsening of long-term congestive heart failure, and cardo-respiratory arrest.

[i] The number of participants for whom the VR-12 Physical Component Score (PCS) and Mental Component Score (MCS) was calculated at Day 28, 60 and 180 was: 173, 180 and 148 in the methylprednisolone group and 166, 156 and 132 in the placebo group. The number of participants for whom the Katz Activities of Daily Living (ADL) score was calculated at Day 28, 60 and 180 was: 177, 183 and 153 in the methylprednisolone group and 167, 159 and 134 in the placebo group. The number of participants for whom the Lawton Instrumental Activities of Daily Living (IADL) score was calculated at Day 28, 60 and 180 was: 177, 180 and 151 in the methylprednisolone group and 167, 159 and 133 in the placebo group.
[j] Among the 433 participants (214 in methylprednisolone group, 219 in placebo group) who were discharged alive from initial hospitalization. Two of the 433 participants had missing rehospitalization data (1 in methylprednisolone group, 1 in placebo group) and were excluded from analysis.
[k] Among the 218 patients (115 in methylprednisolone group, 103 in placebo group) who had at least one rehospitalization within 12 months.
[l] The estimated difference in RMST up to study day 180, adjusted for MV status at randomization in a RMST regression using pseudovalue method, is -0.4 (95% CI -11.0 to 10.2), p=1.00.
[m] Participants who died on initial MV on or prior to day 28 were censored on day 29. 162 participants were included in this analysis (75 in the methylprednisolone group, 87 in the placebo group).

Table S3. Exclusion criteria for the per-protocol analysis.

Criterion for exclusion from the per-protocol analysis	Total (n=584)	Methylprednisolone (n=297)	Placebo (n=287)
Meeting any exclusion criterion – no. (%)	98 (17%)	54 (18%)	44 (15%)
Exclusion criterion [a] (check all that apply) – no./total no. (%)			
Potential violation of inclusion criteria [b]	4 (1%)	3 (1%)	1 (<1%)
Potential violation of exclusion criteria [c]	5 (1%)	3 (1%)	2 (1%)
Did not receive any dose of study drug	9 (2%)	4 (1%)	5 (2%)
Received ≤ 7 days of study drug during study days 1-20, unless died on or before study day 7 [d]	93 (16%)	51 (17%)	42 (15%)
Received any dose of wrong study drug	2 (<1%)	1 (<1%)	1 (<1%)

[a] The exclusion criteria for the per-protocol analysis were developed after the intent to treat analyses were completed.
[b] Conditions that mimic pneumonia discovered after study entry, even though these participants did meet the protocol-specified clinical diagnosis of CAP/HCAP at the time of study entry.
[c] Exclusion criterion unknown at the entry of the study.
[d] No apparent differences in reasons of study drug withdrawal between the two groups.

Table S4. Subgroup analysis on primary outcome

Subgroup	Methylprednisolone (n=297)	Placebo (n=287)	Odds ratio (95% CI)[a]	p-value[b]	Interaction p-value[c]
All participants - no. / total no. (%)	47/286 (16%)	50/277 (18%)	0.89 (0.58 – 1.38)	0.61	
Protocol-specified subgroup analysis					
MV status at randomization - no. / total no. (%)					0.98
MV	22/94 (23%)	24/94 (26%)	0.89 (0.46 – 1.73)	0.73	
Non-MV	25/192 (13%)	26/183 (14%)	0.90 (0.50 – 1.63)	0.74	
APACHE III score quartiles - no. / total no. (%)					0.91
Q1: (0, 34]	8/75 (11%)	10/69 (14%)	0.70 (0.26 – 1.90)	0.49	
Q2: (34, 53.5]	6/64 (9%)	7/70 (10%)	0.93 (0.30 – 2.93)	0.90	
Q3: (53.5, 72]	6/64 (9%)	12/80 (15%)	0.59 (0.21 – 1.66)	0.31	
Q4: (72, 157]	27/83 (33%)	20/57 (35%)	0.89 (0.44 – 1.82)	0.75	
Type of pneumonia					0.98
Community-acquired pneumonia (CAP)	23/111 (21%)	20/85 (24%)	0.85 (0.43 - 1.68)	0.64	
Health care-associated pneumonia (HCAP)	24/175 (14%)	30/192 (16%)	0.86 (0.48 - 1.53)	0.61	
Post-hoc subgroup analysis					
Severity of CAP					0.78
Minor criteria	17/134 (13%)	18/137 (13%)	0.96 (0.47 – 1.95)	0.91	
Vassopressor dependent shock alone	2/13 (15%)	2/8 (25%)	0.55 (0.06 – 4.91)	0.59	
MV alone	21/114 (18%)	25/108 (23%)	0.75 (0.39 – 1.44)	0.39	
Vassopressor dependent Shock and MV	7/25 (28%)	5/24 (21%)	1.48 (0.40 – 5.51)	0.56	
Adequacy of initial antibiotic treatment [d]					0.10
Adequate	34/234 (15%)	43/225 (19%)	0.72 (0.44 – 1.18)	0.19	
Not adequate	11/49 (22%)	6/47 (13%)	1.98 (0.67 – 5.87)	0.21	

Time to study treatment initiation from hospital presentation [e]					0.59
Within 48 hours	22/176 (13%)	26/194 (13%)	0.92 (0.50 – 1.70)	0.80	
Not within 48 hours	25/110 (23%)	24/83 (29%)	0.72 (0.38 – 1.39)	0.33	
ALI-ARDS status at baseline					0.07
ALI-ARDS	4/26 (15%)	14/39 (36%)	0.32 (0.09 – 1.13)	0.07	
No ALI-ARDS	43/260 (17%)	35/237 (15%)	1.14 (0.70 – 1.86)	0.59	

[a] From logistic regression with treatment as the single covariate. The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects.

[b] Chi-square test.

[c] From logistic regression with covariates treatment, subgroup, treatment by subgroup interaction.

[d] Based on microbiological findings and sensitivity results if available; otherwise based on guidelines.

[e] Hospital presentation was defined as the date and time of hospital admission at the current hospital if the participant was not transferred from another hospital. For participants who were transferred from another hospital, hospital presentation was defined as the date and time of first physician encounter at that hospital.

Table S5. Primary and Secondary Outcomes – MV stratum

Outcome	Methylprednisolone (n=97)	Placebo (n=96)	Difference[a] (95% CI)	P-value[b]
Primary Outcome				
Died on or prior to study day 60 – no. / total no. (%)	22/94 (23%)	24/94 (26%)	0.89 (0.46, 1.73) [c]	0.73
Secondary Outcome				
In-hospital morbidity and mortality				
Vasopressor dependent shock during initial hospital stay among those who did not have vasopressor dependent shock at randomization – no. / total no. (%)	9/80 (11%)	7/88 (8%)	1.47 (0.52, 4.14) [d]	1.00
ALI-ARDS during initial hospital stay among those who did not have ALI-ARDS at randomization – no. / total no. (%)	8/75 (11%)	3/69 (4%)	2.63 (0.67, 10.34) [d]	1.00
MODS-free days in study days 1-8 – median (IQR) and no./total no. (%)	0 (0 - 0)	0 (0 - 0)	NE	1.00
0	84/93 (90%)	91/95 (96%)		
1	4/93 (4%)	1/95 (1%)		
2	2/93 (2%)	2/95 (2%)		
3	1/93 (1%)	1/95 (1%)		
4	0/93 (0%)	0/95 (0%)		
5	1/93 (1%)	0/95 (0%)		
6	0/93 (0%)	0/95 (0%)		
7	1/93 (1%)	0/95 (0%)		
8	0/93 (0%)	0/95 (0%)		
MV-free days in study days 1-8 – median (IQR)	4 (0 - 7)	1 (0 - 6)	3 (1.1, 4.9)	0.49
MV-free days in study days 1-28 [e] – median (IQR)	23 (13 - 27)	21 (0 - 26)	2 (-0.8, 4.8)	1.00
Duration of initial ICU stay (from day 0)[f] – median (IQR)	7 (3 - 11)	7 (4 - 15)	0 (-1.9, 1.9)	1.00
Duration of total ICU stay up to study day 28 (from day 0) [f] – median (IQR)	8 (4 - 12)	7 (5 - 16)	1 (-1.5, 3.5)	1.00

Outcome	Methylprednisolone (n=97)	Placebo (n=96)	Difference[a] (95% CI)	P-value[b]
Duration of initial hospital stay (from day 0)[f] – median (IQR)	11 (7 - 16)	13 (7 - 23)	-2.6 (-6.2, 1.1)	0.71
Hospital Mortality – no. / total no. (%)	20/94 (21%)	16/95 (17%)	1.33 (0.64, 2.77)[g]	1.00
Post-discharge morbidity and mortality				
Cardiovascular complications[h] – no. / total no. (%)				
Up to Day 28	3/70 (4%)	2/64 (3%)	1.39 (0.22 - 8.59)	1.00
Up to Day 60	5/74 (7%)	4/76 (5%)	1.30 (0.34 - 5.06)	1.00
Up to Day 180	11/74 (15%)	11/79 (14%)	1.08 (0.44 - 2.66)	1.00
VR-12 Physical Component Score[i]				
Day 28	37.9 ± 13.9	37.4 ± 14.8	0.5 (-5.1, 6.1)	1.00
Day 60	39.4 ± 16.3	39.7 ± 15.0	-0.3 (-6.2, 5.7)	1.00
Day 180	44.1 ± 15.0	42.9 ± 13.5	1.2 (-4.7, 7.0)	1.00
VR-12 Mental Component Score[i]				
Day 28	32.8 ± 9.7	34.8 ± 9.7	-2.0 (-5.8, 1.8)	1.00
Day 60	32.1 ± 9.4	33.2 ± 9.9	-1.1 (-4.8, 2.6)	1.00
Day 180	30.7 ± 7.4	31.5 ± 8.5	-0.9 (-4.1, 2.4)	1.00
Katz ADL[i]				
Day 28	4.89 ± 1.98	4.62 ± 2.18	0.28 (-0.53, 1.09)	1.00
Day 60	4.92 ± 1.73	4.78 ± 1.96	0.13 (-0.57, 0.83)	1.00
Day 180	5.27 ± 1.44	4.69 ± 2.09	0.58 (-0.15, 1.30)	1.00
Lawton IADL[i]				
Day 28	5.12 ± 2.73	5.15 ± 2.59	-0.03 (-1.07, 1.02)	1.00
Day 60	5.12 ± 2.65	5.47 ± 2.71	-0.35 (-1.37, 0.67)	1.00
Day 180	5.74 ± 2.45	5.67 ± 2.68	0.08 (-0.97, 1.12)	1.00
Any rehospitalization within 12 months[j] - no. / total no. (%)	41/74 (55%)	39/78 (50%)	1.24 (0.66 - 2.35)[g]	1.00
Number of rehospitalizations within 12 months[k] - median (IQR)	1 (1 - 3)	2 (1 - 3)	-1 (-1.8, -0.2)	1.00

Outcome	Methylprednisolone (n=97)	Placebo (n=96)	Difference[a] (95% CI)	P-value[b]
Died by study day 180 - no. / total no. (%)	27/94 (29%)	28/94 (30%)	0.95 (0.51, 1.78) [g]	1.00
Restricted mean survival time up to day 180 – RMST (SE)	138.5 (7.2)	137.4 (7.1)	1.1 (-18.8, 20.9)	1.00
Died by 1 year - no. / total no. (%)	32/86 (37%)	36/91 (40%)	0.91 (0.49, 1.66) [g]	1.00
Time to death (days) – no. / total no. (%)	32/97 (33%)	36/96 (38%)	0.89 (0.55, 1.44) [g]	1.00

[a] Difference between treatment group is expressed as: odds ratio for binary variables; difference in medians for MV-free days up to day 8 and day 28, duration of ICU stay, total ICU days up to day 28, duration of initial hospital stay, and number of rehospitalizations within 12 months; difference in means for other continuous variables; hazards ratio for time to event variables. NE: The difference in median and the 95%CI could not be estimated because majority of the observed values were at the one end of the distribution.
[b] The P-values for secondary outcomes are adjusted for multiplicity by Bonferroni correction (for 9 in-hospital outcomes and 21 post-discharge outcomes). The widths of the confidence intervals for the treatment differences in secondary outcomes have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects.
[c] The adjusted odds ratio for 60-day mortality is 0.89 (95%CI, 0.45 - 1.76; p=0.74) when adjusted for site, and is 0.70 (95%CI, 0.32 – 1.54; p=0.37) when adjusted for site, age, APACHE III score, CCI, bacteremia, use of anti-inflammatory medications at baseline and use of macrolide at baseline. The unadjusted absolute risk difference in the 60-day mortality is -2% (95%CI, -14% to 10%).
[d] The unadjusted absolute risk difference is 3% (95%CI, -6% to 12%) for vasopressor dependent shock, and 6% (95%CI, -2% to 15%) for ALI-ARDS.
[e] MV-free days from Days 1-28 was calculated for 181 participants (92 in the methylprednisolone group and 89 in the placebo group).
[f] The number of participants for whom the outcome was calculated in the methylprednisolone and placebo groups was, respectively, duration of initial ICU stay: 95 and 95; duration of total ICU stay up to Day 28: 94 and 95; duration of initial hospital stay: 94 and 95.
[g] The unadjusted methylprednisolone versus placebo absolute risk difference is 4% (95%CI, -7% to 16%) for hospital mortality, 5% (95%CI, -10% to 21%) for rehospitalization within 12 months, -1% (95%CI, -14% to 12%) for 180-day mortality, -2% (95%CI, -17% to 12%) for one-year mortality, and -5% (95%CI, -18% to 9%) for mortality over the study period.
[h] Cardiovascular complications included acute myocardial infarction, serious arrhythmias, new congestive heart failure or acute worsening of long-term congestive heart failure, and cardo-respiratory arrest.
[i] The number of participants for whom the VR-12 Physical Component Score (PCS) and Mental Component Score (MCS) was calculated at Day 28, 60 and 180 was: 56, 59 and 47 in the methylprednisolone group and 47, 50 and 47 in the placebo group. The number of participants for whom the Katz Activities of Daily Living (ADL) score was calculated at Day 28, 60 and 180 was: 57, 59 and 48 in the methylprednisolone group and 47, 51 and 49 in the placebo group. The number of participants for whom the Lawton Instrumental Activities of Daily Living (IADL) score was calculated at Day 28, 60 and 180 was: 57, 58 and 47 in the methylprednisolone group and 47, 51 and 48 in the placebo group.
[j] Among the 153 participants (74 in methylprednisolone group, 79 in placebo group) who were discharged alive from initial hospitalization. One of the 153 participants had missing rehospitalization data (0 in methylprednisolone group, 1 in placebo group) and were excluded from analysis.
[k] Among the 80 patients (41 in methylprednisolone group, 39 in placebo group) who had at least one rehospitalization within 12 months.

Table S6. Primary and Secondary Outcomes – non-MV stratum

Outcome	Methylprednisolone (n=200)	Placebo (n=191)	Difference[a] (95% CI)	P-value[b]
Primary Outcome				
Died on or prior to study day 60 – no. / total no. (%)	25/192 (13%)	26/183 (14%)	0.90 (0.50, 1.63) [c]	0.74
Secondary Outcome				
In-hospital morbidity and mortality				
Vasopressor dependent shock during initial hospital stay among those who did not have vasopressor dependent shock at randomization – no. / total no. (%)	4/194 (2%)	5/183 (3%)	0.75 (0.20, 2.84) [d]	1.00
ALI-ARDS during initial hospital stay among those who did not have ALI-ARDS at randomization – no. / total no. (%)	2/190 (1%)	5/172 (3%)	0.36 (0.07, 1.86) [d]	1.00
MODS-free days in study days 1-8 – median (IQR)	0 (0 - 0)	0 (0 -0)	NE	0.90
0	165/195 (85%)	161/180 (89%)		
1	1/195 (1%)	9/180 (5%)		
2	2/195 (1%)	2/180 (1%)		
3	3/195 (2%)	1/180 (1%)		
4	3/195 (2%)	2/180 (1%)		
5	2/195 (1%)	0/180 (0%)		
6	0/195 (0%)	1/180 (1%)		
7	11/195 (6%)	2/180 (1%)		
8	8/195 (4%)	2/180 (1%)		
MV-free days in study days 1-8 – median (IQR)	8 (8 - 8)	8 (8 - 8)	NE	1.00
MV-free days in study days 1-28 [e] – median (IQR)	28 (28 - 28)	28 (28 - 28)	NE	1.00
Duration of initial ICU stay (from day 0) [f] – median (IQR)	2 (2 - 5)	3 (2 - 5)	-1 (-1.6, - 0.4)	1.00

Outcome	Methylprednisolone (n=200)	Placebo (n=191)	Difference[a] (95% CI)	P-value[b]
Duration of total ICU stay up to study day 28 (from day 0) [f] – median (IQR)	3 (2 - 5)	3 (2 - 5)	0 (-0.6, 0.6)	1.00
Duration of initial hospital stay (from day 0) [f] – median (IQR)	6 (4 - 9)	6 (4 - 10)	0.0 (-1.3, 1.3)	1.00
Hospital Mortality – no. / total no. (%)	14/197 (7%)	12/186 (6%)	1.11 (0.50, 2.47) [g]	1.00
Post-discharge morbidity and mortality				
Cardiovascular complications [h] – no. / total no. (%)				
Up to Day 28	8/181 (4%)	10/170 (6%)	0.74 (0.28 - 1.92)	1.00
Up to Day 60	13/183 (7%)	13/174 (7%)	0.95 (0.43 - 2.10)	1.00
Up to Day 180	20/183 (11%)	19/174 (11%)	1.00 (0.51 - 1.95)	1.00
VR-12 Physical Component Score [i]				
Day 28	37.3 ± 14.0	37.2 ± 13.5	0.1 (-3.2, 3.3)	1.00
Day 60	38.6 ± 14.9	40.6 ± 14.4	-2 (-5.5, 1.5)	1.00
Day 180	40.1 ± 14.8	39.9 ± 16.6	0.2 (-4.0, 4.4)	1.00
VR-12 Mental Component Score [i]				
Day 28	32.6 ± 9.7	33.6 ± 9.2	-1.0 (-3.2, 1.2)	1.00
Day 60	32.5 ± 8.6	31.5 ± 8.6	1.0 (-1.1, 3.1)	1.00
Day 180	31.8 ± 8.5	33.4 ± 9.4	-1.6 (-3.9, 0.8)	1.00
Katz ADL[i]				
Day 28	5.03 ± 1.79	4.79 ± 2.03	0.24 (-0.20, 0.69)	1.00
Day 60	5.19 ± 1.70	5.12 ± 1.75	0.06 (-0.35, 0.47)	1.00
Day 180	5.06 ± 1.75	5.18 ± 1.71	-0.12 (-0.58, 0.33)	1.00
Lawton IADL [i]				
Day 28	5.50 ± 2.57	5.36 ± 2.77	0.14 (-0.48, 0.76)	1.00
Day 60	5.54 ± 2.60	5.81 ± 2.60	-0.27 (-0.89, 0.35)	1.00
Day 180	5.78 ± 2.62	6.10 ± 2.57	-0.32 (-1.01, 0.37)	1.00
Any rehospitalization within 12 months [j] - no. / total no. (%)	94/179 (53%)	81/172 (47%)	1.24 (0.82 - 1.89) [g]	1.00

Outcome	Methylprednisolone (n=200)	Placebo (n=191)	Difference[a] (95% CI)	P-value[b]
Number of rehospitalizations within 12 months [k] - median (IQR)	1 (1 - 3)	2 (1 - 2)	-1 (-1.4, -0.6)	1.00
Died by study day 180 - no. / total no. (%)	32/185 (17%)	37/180 (21%)	0.81 (0.48, 1.37) [g]	1.00
Restricted mean survival time up to day 180 – RMST (SE)	157.7 (4.0)	154.9 (4.2)	2.8 (-8.6, 14.2)	1.00
Died by 1 year - no. / total no. (%)	47/174 (27%)	48/162 (30%)	0.88 (0.55, 1.41) [g]	1.00
Time to death (days) – no. / total no. (%)	47/200 (24%)	48/191 (25%)	0.92 (0.61, 1.37) [g]	1.00

[a] Difference between treatment group is expressed as: odds ratio for binary variables; difference in medians for MV-free days up to day 8 and day 28, duration of ICU stay, total ICU days up to day 28, duration of initial hospital stay, and number of rehospitalizations within 12 months; difference in means for other continuous variables; hazards ratio for time to event variables. NE: The difference in median and the 95%CI could not be estimated because majority of the observed values were at the one end of the distribution.
[b] The P-values for secondary outcomes are adjusted for multiplicity by Bonferroni correction (for 9 in-hospital outcomes and 21 post-discharge outcomes). The widths of the confidence intervals for the treatment differences in secondary have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects.
[c] The adjusted odds ratio for 60-day mortality is 0.90 (95%CI, 0.50 - 1.64; p=0.73) when adjusted for site, and is 0.95 (95%CI, 0.49 – 1.85; p=0.89) when adjusted for site, age, APACHE III score, CCI, bacteremia, use of anti-inflammatory medications at baseline and use of macrolide at baseline. The unadjusted absolute risk difference in the 60-day mortality is -1% (95%CI, -8% to 6%).
[d] The unadjusted absolute risk difference is -1% (95%CI, -4% to 2%) for vasopressor dependent shock, and -2% (95%CI, -5% to 1%) for ALI-ARDS.
[e] MV-free days from Days 1-28 was calculated for 377 participants (195 in the methylprednisolone group and 182 in the placebo group).
[f] The number of participants for whom the outcome was calculated in the methylprednisolone and placebo groups was, respectively, duration of initial ICU stay: 200 and 186; duration of total ICU stay up to Day 28: 197 and 185; duration of initial hospital stay: 197 and 186.
[g] The unadjusted methylprednisolone versus placebo absolute risk difference is 1% (95%CI, -4% to 6%) for hospital mortality, 5% (95%CI, -5% to 16%) for rehospitalization within 12 months, -3% (95%CI, -11% to 5%) for 180-day mortality, -3% (95%CI, -12% to 7%) for one-year mortality, and -2% (95%CI, -10% to 7%) for mortality over the study period.
[h] Cardiovascular complications included acute myocardial infarction, serious arrhythmias, new congestive heart failure or acute worsening of long-term congestive heart failure, and cardo-respiratory arrest.
[i] The number of participants for whom the VR-12 Physical Component Score (PCS) and Mental Component Score (MCS) was calculated at Day 28, 60 and 180 was: 141, 142 and 119 in the methylprednisolone group and 137, 127 and 101 in the placebo group. The number of participants for whom the Katz Activities of Daily Living (ADL) score was calculated at Day 28, 60 and 180 was: 146, 144 and 124 in the methylprednisolone group and 140, 129 and 101 in the placebo group. The number of participants for whom the Lawton Instrumental Activities of Daily Living (IADL) score was calculated at Day 28, 60 and 180 was: 145, 143 and 122 in the methylprednisolone group and 140, 129 and 101 in the placebo group.
[j] Among the 357 participants (183 in methylprednisolone group, 174 in placebo group) who were discharged alive from initial hospitalization. Six of the 357 participants had missing rehospitalization data (4 in methylprednisolone group, 2 in placebo group) and were excluded from analysis.
[k] Among the 175 patients (94 in methylprednisolone group and 81 in placebo group) who had at least one rehospitalization within 12 months.

Table S7. Baseline characteristics – MV stratum

Characteristic	Methylprednisolone (n=97)	Placebo (n=96)
Age - years	68.5 ± 10.6	66.9 ± 10.7
Male sex – no. (%)	95 (98%)	90 (94%)
Ethnicity – no. (%)		
Not Spanish, Hispanic or Latino	79 (87%)	80 (86%)
Mexican, Mexican American, or Chicano	7 (8%)	5 (5%)
Puerto Rican	1 (1%)	5 (5%)
Cuban	0 (0%)	0 (0%)
Other Spanish, Hispanic or Latino	4 (4%)	3 (3%)
Race – no./total no. (%)		
White	78/93 (84%)	73/94 (78%)
Black/African American	14/93 (15%)	19/94 (20%)
Other	5/93 (5%)	4/94 (4%)
BMI ≥ 30 – no./total no. (%)	25/97 (26%)	29/96 (30%)
Smoking status – no./total no. (%)		
Current smoker	39/96 (41%)	29/95 (31%)
Prior smoker (not current smoker)	44/96 (46%)	39/95 (41%)
Lifetime non-smoker	13/96 (14%)	27/95 (28%)
Any major co-morbidity – no./total no. (%)	95/97 (98%)	91/96 (95%)
Number of major co-morbidities	4 ± 1.8	3.8 ± 2.0
Charlson Comorbidity Index	5.84 ± 2.52	5.33 ± 2.14
ACE27 Overall Comorbidity Score – no. (%)		
0	2 (2%)	3 (3%)
1	15 (15%)	11 (11%)
2	13 (13%)	18 (19%)
3	67 (69%)	64 (67%)
ACE27 Total Score	2.49 ± 0.83	2.49 ± 0.82
Karnofsky Performance Score	70.8 ± 22.4	70.2 ± 23.5

Characteristic	Methylprednisolone (n=97)	Placebo (n=96)
Health Care-Associated Pneumonia (HCAP) – no. (%)	35/97 (36%)	30/96 (31%)
Resided in nursing home or long-term care facility immediately prior to hospital admission	13 (13%)	20 (21%)
Hospitalized in acute care hospital for two or more days within past 90 days	25 (26%)	17 (18%)
Received intravenous therapy (antibiotic or chemotherapy) within past 30 days	14 (14%)	9 (9%)
Received home wound care within past 30 days	8 (8%)	3 (3%)
Received hemodialysis within past 30 days	2 (2%)	0 (0%)
Admission from the ward – no. (%)	26/97 (27%)	24/96 (25%)
Time from hospital admission to randomization – days, median (IQR)	1.9 (1.1-2.9)	1.8 (1.1-2.6)
Pneumonia Severity Index (PSI)	137.0 ± 34.4	131.9 ± 36.1
PSI class – no. (%)		
I	0 (0%)	1 (1%)
II	1 (1%)	4 (4%)
III	7 (7%)	6 (6%)
IV	36 (37%)	35 (36%)
V	53 (55%)	50 (52%)
PIRO	2.80 ± 1.03	2.56 ± 1.02
CURB-65	2.73 ± 1.15	2.70 ± 1.16)
Chest Radiograph Score	2.3 ± 1.04	2.22 ± 1.17
Bilateral – no./total no. (%)	68/95 (72%)	66/93 (71%)
Multilobar – no./total no. (%)	74/97 (76%)	70/96 (73%)
PaO2:FiO2 (if PaO2 is available) [a]	155 ± 73	182 ± 97
SpO2:FiO2 (if PaO2 is not available) [b]	195 ± 66	200 ± 58

Characteristic	Methylprednisolone (n=97)	Placebo (n=96)
ALI-ARDS at randomization – no./total no. (%)	19/97 (20%)	26/96 (27%)
Bacteremia – no./total no. (%)	17/91 (19%)	9/93 (10%)
White Blood Cell Count (x10^6cells/mL)	16.19 ± 19.07	13.32 ± 6.46
APACHE III Score	65.6 ± 32.3	66.1 ± 34.3
SAPs III Score	66.0 ± 11.0	64.3 ± 10.6
SOFA Score	8.62 ± 2.93	8.20 ± 3.04
Lactate Level (mmol/L)[c]	1.84 ± 1.07	1.66 ± 1.25
Vasopressor dependent shock at or prior to study entry – no. / total no. (%)	29/97 (30%)	24/96 (25%)
Use of anti-inflammatory medications at baseline – no. / total no. (%)[d]	76/97 (78%)	72/96 (75%)
Use of macrolide antibiotics at baseline – no./total no. (%)	24/97 (25%)	16/96 (17%)
Antibiotic treatment in the participants who were not admitted from other hospital - no. / total no. (%)		
Did not receive initial antibiotics	13/91 (14%)	17/91 (19%)
Received initial antibiotics within 6 hours of hospital admission	75/91 (82%)	70/91 (77%)
Received initial antibiotics beyond 6 hours of hospital admission	3/91 (3%)	4/91 (4%)
Unknown	0/91 (0%)	0/91 (0%)
Adequate initial antibiotic treatment based on guidelines[e] - no. / total no. (%)	94/96 (98%)	90/95 (95%)
Tested for Influenza – no. / total no. (%)	64/96 (67%)	65/94 (69%)
Tested positive for influenza in participants who were tested for influenza – no. / total no. (%)	3/52 (6%)	5/50 (10%)
Tested positive for both influenza and bacteria – no. / total no. (%)	3/97 (3%)	3/96 (3%)

[a] The number of participants who had a PaO2:FiO2 measurement was 166 overall with 86 in the methylprednisolone group and 80 in the placebo group.
[b] The number of participants who had an SpO2:FiO2 measurement was 17 overall with 6 in the methylprednisolone group and 11 in the placebo group.
[c] The number of participants who had a Lactate Level measurement was 173 overall with 88 in the methylprednisolone group and 85 in the placebo group.

[d] 70 (36%) participants used aspirin at baseline (39 in the methylprednisolone group, 31 in the placebo group); and 23 (12%) participants used systemic corticosteroids (12 in methylprednisolone, 11 in placebo).
[e] Excludes participants who did not receive antibiotics within 6 hours of hospital admission

Table S8. Baseline characteristics – non-MV stratum

Characteristic	Methylprednisolone (n=200)	Placebo (n=191)
Age - years	69.2 ± 11	69.5 ± 11.3
Male sex – no. (%)	194 (97%)	183 (96%)
Ethnicity – no. (%)		
Not Spanish, Hispanic or Latino	176 (90%)	171 (91%)
Mexican, Mexican American, or Chicano	9 (5%)	7 (4%)
Puerto Rican	4 (2%)	3 (2%)
Cuban	0 (0%)	1 (1%)
Other Spanish, Hispanic or Latino	6 (3%)	5 (3%)
Race – no./total no. (%)		
White	167/194 (86%)	154/187 (82%)
Black/African American	22/194 (11%)	29/187 (16%)
Other	10/194 (5%)	6/187 (3%)
BMI ≥ 30 – no./total no. (%)	37/200 (19%)	41/189 (22%)
Smoking status – no./total no. (%)		
Current smoker	59/198 (30%)	60/189 (30%)
Prior smoker (not current smoker)	111/198 (56%)	100/189 (53%)
Lifetime non-smoker	28/198 (14%)	29/189 (15%)
Any major co-morbidity – no./total no. (%)	195/200 (98%)	184/189 (97%)
Number of major co-morbidities	4 ± 1.7	4 ± 1.8
Charlson Comorbidity Index	5.75 ± 2.33	5.8 ± 2.28
ACE27 Overall Comorbidity Score – no. (%)		
0	4/200 (2%)	5/189 (3%)
1	23/200 (12%)	22/189 (12%)
2	38/200 (19%)	41/189 (22%)
3	135/200 (68%)	121/189 (64%)
ACE27 Total Score	2.52 ± 0.78	2.47 ± 0.8
Karnofsky Performance Score	73.1 ± 21.8	74.3 ± 21.8

Characteristic	Methylprednisolone (n=200)	Placebo (n=191)
Health Care-Associated Pneumonia (HCAP) – no. (%)	77/200 (39%)	59/191 (31%)
Resided in nursing home or long-term care facility immediately prior to hospital admission	27 (14%)	28 (15%)
Hospitalized in acute care hospital for two or more days within past 90 days	56 (28%)	41 (21%)
Received intravenous therapy (antibiotic or chemotherapy) within past 30 days	28 (14%)	22 (12%)
Received home wound care within past 30 days	10 (5%)	10 (5%)
Received hemodialysis within past 30 days	8 (4%)	8 (4%)
Admission from the ward – no. (%)	40/200 (20%)	33/191 (17%)
Time from hospital admission to randomization – days, median (IQR)	1.5 (0.9-2.0)	1.2 (0.9-1.8)
Pneumonia Severity Index (PSI)	120.1 ± 37.3	117.4 ± 32.5
PSI class – no. (%)		
I	3 (2%)	3 (2%)
II	12 (6%)	9 (5%)
III	34 (17%)	23 (12%)
IV	85 (43%)	91 (48%)
V	66 (33%)	63 (33%)
PIRO	1.81 ± 1.02	1.94 ± 1.08
CURB-65	2.67 ± 0.97	2.54 ± 0.96
Chest Radiograph Score	1.98 ± 1.00	1.8 ± 1.01
Bilateral – no./total no. (%)	121/193 (63%)	97/183 (53%)
Multilobar – no./total no. (%)	142/200 (71%)	118/189 (62%)
PaO2:FiO2 (if PaO2 is available) [a]	201 ± 87	192 ± 84
SpO2:FiO2 (if PaO2 is not available) [b]	290 ± 100	298 ± 96

Characteristic	Methylprednisolone (n=200)	Placebo (n=191)
ALI-ARDS at randomization – no./total no. (%)	7/200 (4%)	13/189 (7%)
Bacteremia – no./total no. (%)	32/191 (17%)	23/182 (13%)
White Blood Cell Count (x10^6cells/mL)	14.78 ± 7.33	15.18 ± 7.54
APACHE III Score	48.9 ± 26.4	46.9 ± 23.0
SAPs III Score	56.3 ± 9.0	55.5 ± 8.1
SOFA Score	5.74 ± 2.55	5.32 ± 2.2
Lactate Level (mmol/L)[c]	1.83 ± 1.34	1.89 ± 2.03
Vasopressor dependent shock at or prior to study entry – no. / total no. (%)	15/199 (8%)	8/189 (4%)
Use of anti-inflammatory medications at baseline – no. / total no. (%)[d]	165/200 (83%)	149/190 (78%)
Use of macrolide antibiotics at baseline – no./total no. (%)	40/200 (20%)	36/190 (19%)
Antibiotic treatment in the participants who were not admitted from other hospital - no. / total no. (%)[e]		
Did not receive initial antibiotics	21/187 (11%)	17/180 (9%)
Received initial antibiotics within 6 hours of hospital admission	157/187 (84%)	152/180 (84%)
Received initial antibiotics beyond 6 hours of hospital admission	8/187 (4%)	5/180 (3%)
Unknown	1/187 (1%)	6/180 (3%)
Adequate initial antibiotic treatment based on guidelines[f] - no. / total no. (%)	192/197 (97%)	175/183 (96%)
Tested for Influenza – no. / total no. (%)	118/198 (60%)	108/183 (59%)
Tested positive for influenza in participants who were tested for influenza – no. / total no. (%)	11/92 (12%)	6/81 (7%)
Tested positive for both influenza and bacteria – no. / total no. (%)	4/200 (2%)	3/191 (2%)

[a] The number of participants who had a PaO2:FiO2 measurement was 213 overall with 115 in the methylprednisolone group and 98 in the placebo group.
[b] The number of participants who had an SpO2:FiO2 measurement was 150 overall with 73 in the methylprednisolone group and 77 in the placebo group.
[c] The number of participants who had a Lactate Level measurement was 341 overall with 173 in the methylprednisolone group and 168 in the placebo group.

[d] 170 (44%) participants used aspirin at baseline (83 in the methylprednisolone group, 87 in the placebo group); and 35 (9%) participants used systemic corticosteroids (19 in methylprednisolone, 16 in placebo).
[e] Excludes one participant with time to initial antibiotic treatment from hospital admission longer than 700 hours. This value was mostly likely due to a data entry error.
[f] Excludes participants who did not receive antibiotics within 6 hours of hospital admission

Table S9. Cause of Death for all deaths and for deaths by Study Day 60.

	All Deaths			Deaths by Study Day 60		
	Total	**Methylprednisolone**	**Placebo**	**Total**	**Methylprednisolone**	**Placebo**
Number Died	163	79	84	97	47	50
Immediate Cause of Death						
MODS	9 (6%)	3 (4%)	6 (7%)	8 (8%)	3 (6%)	5 (10%)
Acute MODS in absence of shock	9	3	6	8	3	5
Central Nervous System Failure	1 (1%)	1 (1%)	0 (0%)	1 (1%)	1 (2%)	0 (0%)
Cerebrovascular accident - ischemic (other than large bleed)	1	1	0	1	1	0
Pulmonary	20 (12%)	7 (9%)	13 (15%)	13 (13%)	5 (11%)	8 (16%)
Refractory - Hypoxemic respiratory failure	5	2	3	4	1	3
Hypoxemic respiratory failure (predominantly)	8	3	5	5	3	2
Hypercapnic respiratory failure (predominantly)	4	1	3	2	0	2
Pulmonary embolism - large	1	0	1	1	0	1
Other pulmonary complications	2	1	1	1	1	0
Cardiovascular	38 (23%)	16 (20%)	22 (26%)	18 (19%)	7 (15%)	11 (22%)
Rapid unexpected cardiac death - in-hospital	9	4	5	5	3	2
Sudden cardiac death (SCD) - out-of-hospital	9	3	6	1	0	1

	All Deaths			Deaths by Study Day 60		
	Total	Methylprednisolone	Placebo	Total	Methylprednisolone	Placebo
Expected cardiac death - in-hospital	4	3	1	2	1	1
Death during refractory shock	12	4	8	9	3	6
Fatal cardiac ischemia/myocardial infarction	1	1	0	0	0	0
Presumed cardiovascular death	2	1	1	0	0	0
Cardiac - other cases	1	0	1	1	0	1
Gastrointestinal-Hepatic-Metabolic	2 (1%)	1 (1%)	1 (1%)	1 (1%)	0 (0%)	1 (2%)
Massive gastrointestinal bleeding	1	1	0	0	0	0
Complications of chronic or end-stage liver failure	1	0	1	1	0	1
Renal	4 (2%)	4 (5%)	0 (0%)	3 (3%)	3 (6%)	0 (0%)
Complications of acute renal failure	1	1	0	1	1	0
Complications of chronic renal failure	2	2	0	2	2	0
Severe electrolytes or metabolic abnormality - not associated with renal failure	1	1	0	0	0	0
Hematopoietic	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Immunity - Oncology	1 (1%)	1 (1%)	0 (0%)	1 (1%)	1 (2%)	0 (0%)

	All Deaths			Deaths by Study Day 60		
	Total	Methylprednisolone	Placebo	Total	Methylprednisolone	Placebo
End-stage tumor - not lung	1	1	0	1	1	0
Infections - sepsis	4 (2%)	3 (4%)	1 (1%)	3 (3%)	2 (4%)	1 (2%)
Pneumonia - at study entry	3	2	1	3	2	1
Pulmonary sepsis - hospital acquired - not related to original pneumonia [Ventilator-associated pneumonia (VAP), recurrent pneumonia, etc.]	1	1	0	0	0	0
Iatrogenic and others	69 (42%)	36 (46%)	33 (39%)	45 (46%)	24 (51%)	21 (42%)
Other (not listed above)	69	36	33	45	24	21
Unknown	15 (9%)	7 (9%)	8 (10%)	4 (4%)	1 (2%)	3 (6%)
Underlying Cause of Death						
MODS	14 (9%)	7 (9%)	7 (8%)	11 (11%)	5 (11%)	6 (12%)
Acute MODS in absence of shock	8	3	5	7	3	4
Chronic refractory MODS	6	4	2	4	2	2
Central Nervous System Failure	4 (2%)	1 (1%)	3 (4%)	2 (2%)	0 (0%)	2 (4%)
Anoxic encephalopathy	1	1	0	0	0	0
Cerebrovascular accident - ischemic (other than large bleed)	1	0	1	0	0	0
Other neurologic disease or event (meningitis, seizure, etc.)	2	0	2	2	0	2

	All Deaths			Deaths by Study Day 60		
	Total	Methylprednisolone	Placebo	Total	Methylprednisolone	Placebo
Pulmonary	48 (29%)	20 (25%)	28 (33%)	32 (33%)	14 (30%)	18 (36%)
Refractory - Hypoxemic respiratory failure	10	4	6	8	3	5
Hypoxemic respiratory failure (predominantly)	21	8	13	18	6	12
Hypercapnic respiratory failure (predominantly)	5	3	2	1	1	0
Pulmonary embolism - large	1	1	0	1	1	0
Other pulmonary complications	11	4	7	4	3	1
Cardiovascular	26 (16%)	14 (18%)	12 (14%)	13 (13%)	8 (17%)	5 (10%)
Rapid unexpected cardiac death - in-hospital	2	0	2	0	0	0
Sudden cardiac death (SCD) - out-of-hospital	3	0	3	2	0	2
Expected cardiac death - in-hospital	2	2	0	2	2	0
Death during refractory shock	2	2	0	1	1	0
Fatal cardiac ischemia/myocardial infarction	2	2	0	0	0	0
Documented arrhythmia without cardiac arrest	1	1	0	0	0	0
Refractory congestive heart failure	8	5	3	6	4	2

	All Deaths			Deaths by Study Day 60		
	Total	Methylprednisolone	Placebo	Total	Methylprednisolone	Placebo
Presumed cardiovascular death	4	1	3	2	1	1
Cardiac - other cases	2	1	1	0	0	0
Gastrointestinal-Hepatic-Metabolic	4 (2%)	2 (3%)	2 (2%)	2 (2%)	1 (2%)	1 (2%)
Massive gastrointestinal bleeding	1	1	0	1	1	0
Acute abdomen (perforation, intestinal ischemia, complications of cholecystitis or pancreatitis, etc.)	1	1	0	0	0	0
Complications of chronic or end-stage liver failure	2	0	2	1	0	1
Renal	4 (2%)	3 (4%)	1 (1%)	1 (1%)	0 (0%)	1 (2%)
Complications of chronic renal failure	4	3	1	1	0	1
Hematopoietic	1 (1%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Thrombocytopenia or coagulopathy with diffuse bleeding	1	1	0	0	0	0
Immunity - Oncology	9 (6%)	5 (6%)	4 (5%)	2 (2%)	1 (2%)	1 (2%)
Malignant tumor - lung	1	1	0	0	0	0
Malignant tumor - not lung	2	1	1	0	0	0
End-stage tumor or metastatic disease - lung origin	1	0	1	1	0	1

	All Deaths			Deaths by Study Day 60		
	Total	Methylprednisolone	Placebo	Total	Methylprednisolone	Placebo
End-stage tumor - not lung	5	3	2	1	1	0
Infections - sepsis	32 (20%)	15 (19%)	17 (20%)	26 (27%)	13 (28%)	13 (26%)
Pneumonia - at study entry	19	9	10	19	9	10
Pulmonary sepsis - hospital acquired - not related to original pneumonia [Ventilator-associated pneumonia (VAP), recurrent pneumonia, etc.]	9	3	6	5	2	3
Non-pulmonary sepsis - hospital acquired	1	1	0	1	1	0
Non-pulmonary sepsis - community-acquired or health care-associated	3	2	1	1	1	0
Iatrogenic and others	7 (4%)	2 (3%)	5 (6%)	4 (4%)	2 (4%)	2 (4%)
Overdose or intoxication	1	0	1	0	0	0
Other (not listed above)	6	2	4	4	2	2
Unknown	14 (9%)	9 (11%)	5 (6%)	4 (4%)	3 (6%)	1 (2%)

Table S10. Cause of Death for deaths during initial hospitalization vs. after discharge from initial hospitalization

	Deaths during initial hospitalization			Death after discharge from initial hospitalization		
	Total	**Methylprednisolone**	**Placebo**	**Total**	**Methylprednisolone**	**Placebo**
Number Died	62	34	28	101	45	56
Immediate Cause of Death						
MODS	6 (10%)	3 (9%)	3 (11%)	3 (3%)	0 (0%)	3 (5%)
Acute MODS in absence of shock	6	3	3	3	0	3
Central Nervous System Failure	1 (2%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Cerebrovascular accident - ischemic (other than large bleed)	1	1	0	0	0	0
Pulmonary	11 (18%)	3 (9%)	8 (29%)	9 (9%)	4 (9%)	5 (9%)
Refractory - Hypoxemic respiratory failure	4	1	3	1	1	0
Hypoxemic respiratory failure (predominantly)	3	1	2	5	2	3
Hypercapnic respiratory failure (predominantly)	2	0	2	2	1	1
Pulmonary embolism - large	1	0	1	0	0	0
Other pulmonary complications	1	1	0	1	0	1
Cardiovascular	12 (19%)	6 (18%)	6 (21%)	26 (26%)	10 (22%)	16 (29%)
Rapid unexpected cardiac death - in-hospital	4	3	1	5	1	4

	Deaths during initial hospitalization			Death after discharge from initial hospitalization		
	Total	Methylprednisolone	Placebo	Total	Methylprednisolone	Placebo
Sudden cardiac death (SCD) - out-of-hospital	0	0	0	9	3	6
Expected cardiac death - in-hospital	1	1	0	3	2	1
Death during refractory shock	6	2	4	6	2	4
Fatal cardiac ischemia/myocardial infarction	0	0	0	1	1	0
Presumed cardiovascular death	0	0	0	2	1	1
Cardiac - other cases	1	0	1	0	0	0
Gastrointestinal-Hepatic-Metabolic	0 (0%)	0 (0%)	0 (0%)	2 (2%)	1 (2%)	1 (2%)
Massive gastrointestinal bleeding	0	0	0	1	1	0
Complications of chronic or end-stage liver failure	0	0	0	1	0	1
Renal	1 (2%)	1 (3%)	0 (0%)	3 (3%)	3 (7%)	0 (0%)
Complications of acute renal failure	0	0	0	1	1	0
Complications of chronic renal failure	1	1	0	1	1	0
Severe electrolytes or metabolic abnormality - not associated with renal failure	0	0	0	1	1	0

	Deaths during initial hospitalization			Death after discharge from initial hospitalization		
	Total	**Methylprednisolone**	**Placebo**	**Total**	**Methylprednisolone**	**Placebo**
Hematopoietic	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Immunity - Oncology	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (2%)	0 (0%)
End-stage tumor - not lung	0	0	0	1	1	0
Infections - sepsis	3 (5%)	2 (6%)	1 (4%)	1 (1%)	1 (2%)	0 (0%)
Pneumonia - at study entry	3	2	1	0	0	0
Pulmonary sepsis - hospital acquired - not related to original pneumonia [Ventilator-associated pneumonia (VAP), recurrent pneumonia, etc.]	0	0	0	1	1	0
Iatrogenic and others	28 (45%)	18 (53%)	10 (36%)	41 (41%)	18 (40%)	23 (41%)
Other (not listed above)	28	18	10	41	18	23
Unknown	0 (0%)	0 (0%)	0 (0%)	15 (15%)	7 (16%)	8 (14%)
Underlying Cause of Death						
MODS	9 (15%)	4 (12%)	5 (18%)	5 (5%)	3 (7%)	2 (4%)
Acute MODS in absence of shock	7	3	4	1	0	1
Chronic refractory MODS	2	1	1	4	3	1
Central Nervous System Failure	1 (2%)	0 (0%)	1 (4%)	3 (3%)	1 (2%)	2 (4%)
Anoxic encephalopathy	0	0	0	1	1	0

	Deaths during initial hospitalization			Death after discharge from initial hospitalization		
	Total	**Methylprednisolone**	**Placebo**	**Total**	**Methylprednisolone**	**Placebo**
Cerebrovascular accident - ischemic (other than large bleed)	0	0	0	1	0	1
Other neurologic disease or event (meningitis, seizure, etc.)	1	0	1	1	0	1
Pulmonary	26 (42%)	13 (38%)	13 (46%)	22 (22%)	7 (16%)	15 (27%)
Refractory - Hypoxemic respiratory failure	9	4	5	1	0	1
Hypoxemic respiratory failure (predominantly)	13	5	8	8	3	5
Hypercapnic respiratory failure (predominantly)	0	0	0	5	3	2
Pulmonary embolism - large	1	1	0	0	0	0
Other pulmonary complications	3	3	0	8	1	7
Cardiovascular	6 (10%)	5 (15%)	1 (4%)	20 (20%)	9 (20%)	11 (20%)
Rapid unexpected cardiac death - in-hospital	0	0	0	2	0	2
Sudden cardiac death (SCD) - out-of-hospital	0	0	0	3	0	3
Expected cardiac death - in-hospital	2	2	0	0	0	0
Death during refractory shock	1	1	0	1	1	0

	Deaths during initial hospitalization			Death after discharge from initial hospitalization		
	Total	**Methylprednisolone**	**Placebo**	**Total**	**Methylprednisolone**	**Placebo**
Fatal cardiac ischemia/myocardial infarction	0	0	0	2	2	0
Documented arrhythmia without cardiac arrest	0	0	0	1	1	0
Refractory congestive heart failure	2	1	1	6	4	2
Presumed cardiovascular death	1	1	0	3	0	3
Cardiac - other cases	0	0	0	2	1	1
Gastrointestinal-Hepatic-Metabolic	1 (2%)	1 (3%)	0 (0%)	3 (3%)	1 (2%)	2 (4%)
Massive gastrointestinal bleeding	1	1	0	0	0	0
Acute abdomen (perforation, intestinal ischemia, complications of cholecystitis or pancreatitis, etc.)	0	0	0	1	1	0
Complications of chronic or end-stage liver failure	0	0	0	2	0	2
Renal	0 (0%)	0 (0%)	0 (0%)	4 (4%)	3 (7%)	1 (2%)
Complications of chronic renal failure	0	0	0	4	3	1
Hematopoietic	0 (0%)	0 (0%)	0 (0%)	1 (1%)	1 (2%)	0 (0%)
Thrombocytopenia or coagulopathy with diffuse bleeding	0	0	0	1	1	0

	Deaths during initial hospitalization			Death after discharge from initial hospitalization		
	Total	**Methylprednisolone**	**Placebo**	**Total**	**Methylprednisolone**	**Placebo**
Immunity - Oncology	1 (2%)	0 (0%)	1 (4%)	8 (8%)	5 (11%)	3 (5%)
Malignant tumor - lung	0	0	0	1	1	0
Malignant tumor - not lung	0	0	0	2	1	1
End-stage tumor or metastatic disease - lung origin	1	0	1	0	0	0
End-stage tumor - not lung	0	0	0	5	3	2
Infections - sepsis	17 (27%)	10 (29%)	7 (25%)	15 (15%)	5 (11%)	10 (18%)
Pneumonia - at study entry	13	7	6	6	2	4
Pulmonary sepsis - hospital acquired - not related to original pneumonia [Ventilator-associated pneumonia (VAP), recurrent pneumonia, etc.]	2	1	1	7	2	5
Non-pulmonary sepsis - hospital acquired	1	1	0	0	0	0
Non-pulmonary sepsis - community-acquired or health care-associated	1	1	0	2	1	1
Iatrogenic and others	1 (2%)	1 (3%)	0 (0%)	6 (6%)	1 (2%)	5 (9%)
Overdose or intoxication	0	0	0	1	0	1
Other (not listed above)	1	1	0	5	1	4
Unknown	0 (0%)	0 (0%)	0 (0%)	14 (14%)	9 (20%)	5 (9%)

Table S11. Number of participants with SAEs within 180 days after randomization

	Methylprednisolone (n = 297)	Placebo (n = 287)
Participants with at least 1 SAE	167 (56%)	162 (56%)
Blood and lymphatic system disorders	9	6
Anaemia	4	5
Blood disorder	1	0
Haemorrhagic disorder	2	1
Immune thrombocytopenic purpura	1	0
Leukocytosis	1	0
Cardiac disorders	37 (12%)	45 (16%)
Acute myocardial infarction	2	6
Angina pectoris	1	0
Angina unstable	0	1
Aortic valve stenosis	0	1
Atrial fibrillation	4	5
Atrial flutter	1	1
Atrioventricular block complete	1	0
Bradycardia	0	1
Cardiac arrest	0	2
Cardiac failure	1	5
Cardiac failure congestive	25	18
Cardiac tamponade	0	1
Cardiomyopathy	0	1
Cardio-respiratory arrest	1	1
Chordae tendinae rupture	1	0
Conduction disorder	0	1
Coronary artery disease	0	2
Coronary artery occlusion	0	1

	Methylprednisolone (n = 297)	Placebo (n = 287)
Coronary artery stenosis	0	2
Ischaemic cardiomyopathy	0	1
Palpitations	1	0
Pulseless electrical activity	1	0
Supraventricular tachycardia	1	0
Tachyarrhythmia	1	0
Tachycardia	1	0
Ventricular fibrillation	0	1
Ventricular tachycardia	0	1
Congenital, familial and genetic disorders	0 (0%)	1 (0.3%)
Haemorrhagic arteriovenous malformation	0	1
Endocrine disorders	1 (0.3%)	0 (0%)
Diabetes insipidus	1	0
Gastrointestinal disorders	16 (5%)	11 (4%)
Alcoholic pancreatitis	1	0
Colitis	0	1
Diarrhoea	1	0
Diverticulum intestinal	1	0
Diverticulum intestinal haemorrhagic	0	1
Dysphagia	1	0
Gastric ulcer	0	1
Gastritis	1	0
Gastrointestinal haemorrhage	3	1
Gastrointestinal polyp haemorrhage	1	0
Gastrointestinal ulcer haemorrhage	1	0
Haematemesis	1	0
Hiatus hernia	0	1

	Methylprednisolone (n = 297)	Placebo (n = 287)
Ileus paralytic	0	1
Mallory-Weiss syndrome	0	1
Oesophageal fistula	1	0
Oesophageal varices haemorrhage	0	1
Pancreatitis acute	1	2
Pancreatitis necrotising	0	1
Rectal ulcer	1	0
Salivary hypersecretion	1	0
Small intestinal obstruction	1	0
Upper gastrointestinal haemorrhage	0	1
Volvulus	1	0
General disorders and administration site conditions	17 (6%)	10 (3%)
Adverse drug reaction	3	1
Complication associated with device	1	0
Death	2	1
Impaired healing	1	0
Multiple organ dysfunction syndrome	9	5
Non-cardiac chest pain	1	1
Sudden cardiac death	0	2
Vascular stent restenosis	0	1
Hepatobiliary disorders	2 (1%)	3 (1%)
Bile duct obstruction	0	1
Cholecystitis acute	0	1
Hepatic cirrhosis	1	1
Hepatitis chronic active	0	1
Liver disorder	1	0
Immune system disorders	1 (0%)	0 (0%)

	Methylprednisolone (n = 297)	Placebo (n = 287)
Anaphylactic reaction	1	0
Infections and infestations	59 (20%)	56 (20%)
Arthritis bacterial	1	0
Bacteraemia	0	1
Bronchitis	2	0
Bronchopulmonary aspergillosis	1	0
Cellulitis	3	0
Clostridium difficile colitis	4	3
Clostridium difficile infection	2	0
Clostridium difficile sepsis	0	1
Empyema	1	1
Gangrene	0	1
Implant site infection	1	0
Infectious pleural effusion	1	1
Influenza	0	1
Lower respiratory tract infection	1	0
Lung abscess	1	0
Meningitis listeria	1	0
Osteomyelitis	1	1
Pancreatic abscess	0	1
Pneumonia	27	38
Pneumonia bacterial	1	1
Pneumonia cryptococcal	0	1
Pneumonia haemophilus	2	0
Pneumonia necrotising	0	1
Pneumonia pneumococcal	1	0
Pneumonia pseudomonal	1	1

	Methylprednisolone (n = 297)	Placebo (n = 287)
Pneumonia staphylococcal	0	1
Pneumonia streptococcal	2	0
Post procedural infection	1	0
Sepsis	4	3
Septic shock	3	0
Staphylococcal bacteraemia	0	1
Tracheobronchitis	0	1
Urinary tract infection	6	5
Urosepsis	1	0
Vaccine breakthrough infection	0	1
Injury, poisoning and procedural complications	11 (4%)	8 (3%)
Accidental overdose	0	1
Arterial injury	1	0
Endotracheal intubation complication	1	0
Fall	1	1
Feeding tube complication	1	1
Heat stroke	1	0
Iatrogenic injury	0	1
Intentional overdose	0	1
Joint injury	0	1
Overdose	1	0
Procedural complication	2	0
Procedural hypotension	1	0
Procedural pneumothorax	1	0
Pubis fracture	1	0
Rib fracture	0	1
Toxicity to various agents	1	1

	Methylprednisolone (n = 297)	Placebo (n = 287)
Tracheostomy malfunction	1	0
Wound complication	1	0
Investigations	2 (1%)	1 (0%)
Blood creatinine increased	1	0
Laboratory test abnormal	0	1
Transaminases increased	1	0
Metabolism and nutrition disorders	11 (4%)	7 (2%)
Decreased appetite	1	0
Dehydration	3	0
Diabetic complication	0	1
Diabetic ketoacidosis	1	1
Failure to thrive	1	0
Fluid overload	0	1
Hyperglycaemia	2	1
Hyperkalaemia	1	1
Hyperosmolar hyperglycaemic state	0	1
Hypoglycaemia	2	3
Musculoskeletal and connective tissue disorders	3 (1%)	6 (2%)
Arthritis	0	1
Lumbar spinal stenosis	0	1
Muscular weakness	1	1
Musculoskeletal chest pain	1	0
Osteoarthritis	0	1
Osteonecrosis	0	1
Rhabdomyolysis	1	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	6 (2%)	6 (2%)
Adenocarcinoma gastric	1	0

	Methylprednisolone (n = 297)	Placebo (n = 287)
Bladder neoplasm	0	1
Bronchial carcinoma	1	0
Chronic lymphocytic leukaemia	1	0
Lung adenocarcinoma	1	1
Lung neoplasm malignant	1	0
Myelodysplastic syndrome	1	0
Oesophageal carcinoma	0	1
Plasma cell myeloma	1	0
Prostate cancer metastatic	0	1
Squamous cell carcinoma of lung	0	1
Tonsil cancer	0	1
Nervous system disorders	13 (4%)	11 (4%)
Amyotrophic lateral sclerosis	0	1
Basal ganglia stroke	0	1
Carotid artery aneurysm	0	1
Carotid artery stenosis	1	0
Cerebral ischaemia	0	1
Cerebrovascular accident	6	3
Hypoxic-ischaemic encephalopathy	2	0
Myoclonic epilepsy	1	0
Myxoedema coma	1	0
Parkinson's disease	2	0
Seizure	0	2
Status epilepticus	0	1
Syncope	2	0
Vascular dementia	0	1
Product issues	0 (0%)	1 (0%)

	Methylprednisolone (n = 297)	Placebo (n = 287)
Unintentional medical device removal	0	1
Psychiatric disorders	8 (3%)	13 (5%)
Alcohol abuse	0	1
Alcohol withdrawal syndrome	0	1
Delirium	4	3
Delirium tremens	1	1
Drug abuse	1	0
Drug dependence	0	1
Mental status changes	1	4
Substance-induced psychotic disorder	1	0
Suicidal ideation	2	2
Renal and urinary disorders	17 (6%)	9 (3%)
Acute kidney injury	11	6
Chronic kidney disease	1	0
End stage renal disease	3	0
Glomerulonephritis rapidly progressive	1	0
Nephrolithiasis	0	1
Pulmonary renal syndrome	1	0
Renal failure	1	1
Urinary retention	1	1
Reproductive system and breast disorders	0 (0%)	1 (0%)
Benign prostatic hyperplasia	0	1
Respiratory, thoracic and mediastinal disorders	51 (17%)	56 (20%)
Acute respiratory distress syndrome	4	3
Acute respiratory failure	3	0
Alveolitis allergic	1	0
Aspiration	0	1

	Methylprednisolone (n = 297)	Placebo (n = 287)
Bronchial secretion retention	0	1
Bronchospasm	0	1
Chronic obstructive pulmonary disease	11	16
Dyspnoea	2	0
Haemoptysis	1	1
Haemothorax	1	0
Hypoventilation	1	0
Hypoxia	1	1
Increased bronchial secretion	0	1
Interstitial lung disease	3	2
Lung infiltration	0	1
Organising pneumonia	2	1
Pickwickian syndrome	1	0
Pleural effusion	2	4
Pleuritic pain	0	1
Pneumonia aspiration	5	8
Pneumonitis	1	0
Pneumothorax	3	2
Pulmonary embolism	5	6
Pulmonary fibrosis	0	1
Pulmonary hypertension	1	0
Pulmonary oedema	2	1
Respiratory arrest	2	0
Respiratory failure	9	8
Sleep apnea syndrome	0	1
Skin and subcutaneous tissue disorders	1 (0%)	0 (0%)
Diabetic foot	1	0

	Methylprednisolone (n = 297)	Placebo (n = 287)
Surgical and medical procedures	3 (1%)	1 (0%)
Medical device battery replacement	0	1
Rehabilitation therapy	2	0
Withdrawal of life support	1	0
Vascular disorders	8 (3%)	10 (3%)
Aortic aneurysm	1	0
Aortic stenosis	1	0
Arterial thrombosis	0	1
Arteriosclerosis	0	1
Deep vein thrombosis	1	2
Dry gangrene	0	1
Haematoma	0	1
Hypertension	0	1
Hypertensive crisis	1	0
Hypertensive emergency	0	1
Hypotension	1	1
Orthostatic hypotension	3	0
Shock	0	2

Table S12. Number of participants with complications within 180 days after randomization

	Methylprednisolone (n=297)	Placebo (n=287)	P-value
Number of Participants with Complications	185 (62%)	183 (64%)	0.71
Infections	73 (25%)	76 (26%)	0.60
Cardiovascular	104 (35%)	91 (32%)	0.40
Vasopressor Dependent Shock	18 (6%)	17 (6%)	0.94
Acute Myocardial Infarction	6 (2%)	9 (3%)	0.39
Troponin Elevation Without Acute ECG Changes	24 (8%)	18 (6%)	0.40
Congestive Heart Failure (New or Worsening)	33 (11%)	25 (9%)	0.33
New Serious Atrial Arrhythmia	26 (9%)	14 (5%)	0.06
New Serious Ventricular Arrhythmia	8 (3%)	7 (2%)	0.85
Cardio-Respiratory Arrest (survived or died)	10 (3%)	19 (7%)	0.07
Cardio-Respiratory Arrest-Survived	4 (1%)	10 (3%)	0.09
Cardio-Respiratory Arrest-Died	6 (2%)	12 (4%)	0.13
Deep Vein Thrombosis	2 (1%)	5 (2%)	0.28
Other	42 (14%)	41 (14%)	0.96
Pulmonary	71 (24%)	86 (30%)	0.10
Pleural effusion	23 (8%)	34 (12%)	0.09
Pneumothorax	8 (3%)	4 (1%)	0.27
Pulmonary embolus	6 (2%)	6 (2%)	0.95
Vomiting with aspiration	1 (0%)	3 (1%)	0.37
ALI-ARDS	11 (4%)	13 (5%)	0.62
Acute respiratory failure requiring MV	14 (5%)	7 (2%)	0.14
Other	36 (12%)	51 (18%)	0.06
Gastrointestinal OR Hepatic	37 (12%)	29 (10%)	0.37
Gastrointestinal bleeding	9 (3%)	5 (2%)	0.31
Acute Liver function test abnormalities	11 (4%)	6 (2%)	0.25

Pancreatitis	1 (0%)	3 (1%)	0.37
Impaired swallowing mechanisms after extubation	4 (1%)	4 (1%)	1.00
Other	17 (6%)	17 (6%)	0.92
Hematologic	47 (16%)	37 (13%)	0.31
Anemia	28 (9%)	28 (10%)	0.89
Leucopenia (WBC < 3,000)	3 (1%)	1 (0%)	0.62
Thrombocytopenia	14 (5%)	9 (3%)	0.33
Other	18 (6%)	8 (3%)	0.06
Renal	52 (18%)	40 (14%)	0.24
Acute renal failure requiring dialysis	15 (5%)	13 (5%)	0.77
Hypokalemia	13 (4%)	12 (4%)	0.91
Hypernatremia	9 (3%)	9 (3%)	0.94
Other	29 (10%)	20 (7%)	0.22
Neurologic	30 (10%)	29 (10%)	1.00
Cerebrovascular accident	4 (1%)	3 (1%)	1.00
Encephalopathy	9 (3%)	2 (1%)	0.04
Neuromuscular weakness	7 (2%)	13 (5%)	0.15
Convulsions	1 (0%)	3 (1%)	0.37
Other	17 (6%)	13 (5%)	0.51
Musculoskeletal	9 (3%)	12 (4%)	0.46
Tendonitis	0 (0%)	1 (0%)	0.49
Tendon rupture	0 (0%)	0 (0%)	
Other	9 (3%)	11 (4%)	0.59
Psychiatric	14 (5%)	14 (5%)	0.93
Psychosis	3 (1%)	4 (1%)	0.72
Other new or worsened psychiatric symptoms	7 (2%)	7 (2%)	0.95
Other	6 (2%)	6 (2%)	0.95

Endocrinological	52 (18%)	39 (14%)	0.19
Hyperglycemia requiring insulin	46 (15%)	33 (11%)	0.16
Hypoglycemia requiring glucose	6 (2%)	12 (4%)	0.13
Other	5 (2%)	1 (0%)	0.22